

08/468145

Trying 3106016892...Open

```
Welcome to STN International! Enter x:x  
LOGINID:ssspta1813nxm  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2
```

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI

| | |
|--------------|--|
| NEWS EXPRESS | July 11 CURRENT WINDOWS VERSION IS V6.0b,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:32:54 ON 17 JUL 2001

=> file embase medline biosis uspatfull japio wpids caplus agricola lifesci
biotechds jicst-eplus

| COST IN U.S. DOLLARS | SINCE FILE
ENTRY | TOTAL
SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.30 | 0.30 |

FILE 'EMBASE' ENTERED AT 12:33:40 ON 17 JUL 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:33:40 ON 17 JUL 2001

FILE 'BIOSIS' ENTERED AT 12:33:40 ON 17 JUL 2001

COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 12:33:40 ON 17 JUL 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 12:33:40 ON 17 JUL 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 12:33:40 ON 17 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 12:33:40 ON 17 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 12:33:40 ON 17 JUL 2001

FILE 'LIFESCI' ENTERED AT 12:33:40 ON 17 JUL 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 12:33:40 ON 17 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 12:33:40 ON 17 JUL 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

=> e engel jurgen/au

| | | |
|-----|-----|---------------------|
| E1 | 1 | ENGEL JULIE S/AU |
| E2 | 2 | ENGEL JUNE/AU |
| E3 | 208 | --> ENGEL JURGEN/AU |
| E4 | 1 | ENGEL JURGN/AU |
| E5 | 18 | ENGEL JUTTA/AU |
| E6 | 442 | ENGEL K/AU |
| E7 | 11 | ENGEL K A/AU |
| E8 | 21 | ENGEL K C/AU |
| E9 | 6 | ENGEL K E/AU |
| E10 | 2 | ENGEL K G/AU |
| E11 | 108 | ENGEL K H/AU |
| E12 | 8 | ENGEL K J/AU |

=> s e3-e4

L1 209 ("ENGEL JURGEN"/AU OR "ENGEL JURGN"/AU)

=> e wichert burkhard/au

| | | |
|-----|----|-------------------------|
| E1 | 1 | WICHERT BOB/AU |
| E2 | 1 | WICHERT BODO/AU |
| E3 | 11 | --> WICHERT BURKHARD/AU |
| E4 | 1 | WICHERT BURKHARD V/AU |
| E5 | 5 | WICHERT C/AU |
| E6 | 9 | WICHERT D/AU |
| E7 | 1 | WICHERT D M/AU |
| E8 | 6 | WICHERT E/AU |
| E9 | 2 | WICHERT E V O N/AU |
| E10 | 8 | WICHERT EDWARD/AU |
| E11 | 5 | WICHERT F/AU |
| E12 | 2 | WICHERT FRIEDEL/AU |

=> s e3-e4

L2 12 ("WICHERT BURKHARD"/AU OR "WICHERT BURKHARD V"/AU)

=> e sauerbiar deiter/au

| | | |
|-----|-----|-------------------------|
| E1 | 150 | SAUERBERG PER/AU |
| E2 | 1 | SAUERBERG S K/AU |
| E3 | 0 | --> SAUERBIAR DEITER/AU |
| E4 | 1 | SAUERBIE W/AU |
| E5 | 2 | SAUERBIE WALTER/AU |
| E6 | 4 | SAUERBIER A/AU |
| E7 | 4 | SAUERBIER ARNIM/AU |
| E8 | 1 | SAUERBIER B/AU |
| E9 | 1 | SAUERBIER C/AU |
| E10 | 3 | SAUERBIER C E/AU |
| E11 | 7 | SAUERBIER CHARLES E/AU |
| E12 | 2 | SAUERBIER CHRISTIANE/AU |

=> e sauerbier deiter/au

| | | |
|-----|----|-------------------------|
| E1 | 2 | SAUERBIER CHRISTIANE/AU |
| E2 | 14 | SAUERBIER D/AU |
| E3 | 0 | --> SAUERBIER DEITER/AU |
| E4 | 1 | SAUERBIER DIESTER/AU |
| E5 | 27 | SAUERBIER DIETER/AU |
| E6 | 1 | SAUERBIER E/AU |
| E7 | 1 | SAUERBIER F/AU |
| E8 | 3 | SAUERBIER G A/AU |
| E9 | 18 | SAUERBIER H/AU |
| E10 | 4 | SAUERBIER HEINZ/AU |
| E11 | 1 | SAUERBIER HERBERT/AU |
| E12 | 72 | SAUERBIER I/AU |

=> s e2-e5

L3 42 ("SAUERBIER D"/AU OR "SAUERBIER DEITER"/AU OR "SAUERBIER
DIESTER
"/AU OR "SAUERBIER DIETER"/AU)

=> e reissmann thomas/au

| | | |
|-----|----|-------------------------|
| E1 | 2 | REISSMANN T L/AU |
| E2 | 8 | REISSMANN TH/AU |
| E3 | 38 | --> REISSMANN THOMAS/AU |
| E4 | 6 | REISSMANN THOMAS L/AU |
| E5 | 7 | REISSMANN U/AU |
| E6 | 2 | REISSMANN ULRICH/AU |
| E7 | 9 | REISSMANN ULRIKE/AU |
| E8 | 2 | REISSMANN W/AU |
| E9 | 1 | REISSMANN WALTER/AU |
| E10 | 12 | REISSMANN Z/AU |
| E11 | 2 | REISSMUELL A/AU |
| E12 | 1 | REISSMUELL J/AU |

=> s e1-e4

L4 54 ("REISSMANN T L"/AU OR "REISSMANN TH"/AU OR "REISSMANN
THOMAS"/A
U OR "REISSMANN THOMAS L"/AU)

=> s l1-l4

L5 284 (L1 OR L2 OR L3 OR L4)

=> s 15 and cetrorelix

L6 52 L5 AND CETRORELIX

=> dup rem 16

PROCESSING COMPLETED FOR L6
L7 38 DUP REM L6 (14 DUPLICATES REMOVED)

=> s 17 and (infertil? or fertili?)

UNMATCHED LEFT PARENTHESIS 'AND (INFERTIL?'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s 17 and (infertil? or fertili?)

L8 11 L7 AND (INFERTIL? OR FERTILI?)

=> d bib ab 1-11

L8 ANSWER 1 OF 11 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 95280014 EMBASE
DN 1995280014
TI Development and applications of luteinizing hormone-releasing hormone
antagonists in the treatment of **infertility**: An overview.
AU Reissmann Th.; Felberbaum R.; Diedrich K.; Engel J.;
Comaru-Schally A.M.; Schally A.V.
CS ASTA Medica AG, Frankfurt-M, Germany
SO Human Reproduction, (1995) 10/8 (1974-1981).
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
010 Obstetrics and Gynecology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB Luteinizing hormone-releasing hormone (LHRH) plays a crucial role in
controlling the ovarian cycle in women. By modification of the molecular
structure of this decapeptide, analogues were synthesized with agonistic
or antagonistic effects on the gonadotrophic cells of the anterior
pituitary gland. The agonists, after an initial stimulatory effect
('flare
up'), lead to desensitization of the gonadotrophic cells and a reduction
in the number of LHRH receptors on the cell membrane ('down-regulation'),
while the antagonists produce an immediate effect by competitive blockade
of the LHRH receptors. After administration of LHRH antagonists, the
serum
levels of FSH and LH decrease within hours. Nevertheless, the
adenohypophysis maintains its responsiveness to an LHRH stimulus
('pituitary response') after pretreatment with an antagonist. This
different pharmacological mechanism of LHRH antagonists makes possible
new
approaches to ovarian stimulation and to the therapy of sex steroid
dependent diseases. The premature LH surge, the main cause of
cancellation
during induction of superovulation in assisted reproduction technology
(ART) programmes, can be abolished by short term application of an LHRH
antagonist associated with a reduced human menopausal gonadotrophin (HMG)
requirement for ovarian stimulation. A future approach to ART might be
based on the combination of pretreatment with an LHRH antagonist and
ovulation induction by native LHRH or an agonist. The severe side effects
encountered with early LHRH antagonists, such as anaphylactoid reactions
due to histamine release, are almost completely eliminated in modern
antagonists, especially **Cetrorelix** which is presently used

clinically in controlled phase II clinical studies.

L8 ANSWER 2 OF 11 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 94179320 EMBASE
DN 1994179320
TI Introduction of LHRH-antagonists into the treatment of gynaecological disorders.
AU Reissmann Th.; Diedrich K.; Comaru-Schally A.M.; Schally A.V.
CS Clinic Obstetrics and Gynaecology, University of Lubeck, Lubeck, Germany
SO Human Reproduction, (1994) 9/5 (767-769).
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; (Short Survey)
FS 010 Obstetrics and Gynecology
021 Developmental Biology and Teratology
030 Pharmacology
037 Drug Literature Index
LA English

L8 ANSWER 3 OF 11 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1998:409001 BIOSIS
DN PREV199800409001
TI The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist **cetrorelix**.
AU Albano, Carola (1); Grimbizis, Grigoris; Smits, Johan;
Riethmueller-Winzen, Hilde; Reissmann, Thomas; Van Steirteghem,
Andre; Devroey, Paul
CS (1) Centre Reproductive Med., Brussels Free Univ., Laarbeeklaan 101, 1090
Brussels Belgium
SO Fertility and Sterility, (Aug., 1998) Vol. 70, No. 2, pp. 357-359.
ISSN: 0015-0282.
DT Article
LA English
AB Objective: To analyze the luteal phase of six patients undergoing controlled ovarian hyperstimulation (COH) with hMG and a new GnRH antagonist, **Cetrorelix**, without receiving luteal phase supplementation. Design: Phase II study involving the first six patients who did not receive luteal phase support. Setting: Tertiary referral center. Patient(s): Six healthy women undergoing COH for assisted reproductive techniques. Intervention(s): Oocyte retrieval was performed 36 hours after hCG administration, followed by embryo transfer 2 days later. No luteal phase supplementation was given. Main Outcome Measure(s): Serum E2, progesterone, LH, and FSH concentrations were measured. Result(s): The length of the luteal phase was >12 days in three of the six patients. One of the patients in whom the luteal phase was >12 days had a low serum progesterone concentration (2.9 ng/mL) on day 10. Serum LH concentrations decreased after the preovulatory hCG injection in all patients. However, a progressive increase in LH was observed after day 7, reaching normal values. Conclusion(s): Corpus luteum function seems to be impaired in cycles that are stimulated with hMG and the GnRH antagonist **Cetrorelix**.

L8 ANSWER 4 OF 11 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1995:415178 BIOSIS
DN PREV199598429478
TI Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (**Cetrorelix**) in women with tubal **infertility**
AU Felberbaum, Ricardo E. (1); Reissmann, Thomas; Kuepker,
Wolfgang; Bauer, Otmar; Al Hasani, Safaa; Diedrich, Christa; Diedrich,
Klaus

CS (1) Dep. of Obstetrics and Gynecology, Medical Univ. of Luebeck, Luebeck
Germany

SO European Journal of Obstetrics & Gynecology and Reproductive Biology,
(1995) Vol. 61, No. 2, pp. 151-155.
ISSN: 0301-2115.

DT Article

LA English

AB Objective: To examine the pituitary response in patients undergoing short-term application of the GnRH antagonist **Cetrorelix** in the mid-cycle phase for hypophysial suppression of premature LH surges within an IVF-program. Design: Twenty patients suffering from primary or secondary tubal **infertility** were stimulated with hMG from cycle day 2. From day 7 till ovulation induction **Cetrorelix** was administered in two different dose regimens (15 patients 3 mg s.c. daily; 5 patients 1 mg s.c. daily). Three hours before ovulation induction a GnRH test was performed using 25 mu-g of native GnRH and the pituitary response examined by measurement of the serum LH concentration after 30 min.

Results: Premature LH surges could be avoided in the 3-mg group and in the 1-mg group, respectively. Due to this, none of the cycles had to be cancelled. Oestradiol profiles and ultrasound demonstrated a satisfactory follicular maturation. All patients showed pronounced suppression of the serum LH levels before ovulation induction. The mean increase of serum LH due to the performed GnRH test was 10 mIU/ml for the 3-mg group, while the average maximum in the 1-mg group was about 32.5 mIU/ml. Conclusions: The pituitary response is preserved by the treatment with the GnRH antagonist **Cetrorelix**. The extent of suppression of the adenohypophysis, as expressed by the different reactions on GnRH test, can be modulated by the dosage administered. This should allow ovulation induction by GnRH or one of its agonists instead of hCG, which could be beneficial in patients at high risk of Ovarian Hyperstimulation Syndrome (OHSS) and those suffering from Polycystic Ovary Disease (PCOD).

L8 ANSWER 5 OF 11 USPATFULL
AN 97:78416 USPATFULL

TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases

IN Engel, Jürgen, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of

PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)

PI US 5663145 19970902
AI US 1994-354838 19941208 (8)

PRAI DE 1993-4342091 19931209

DT Utility
FS Granted

EXNAM Primary Examiner: Russel, Jeffrey E.

LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 7

DRWN No Drawings

LN.CNT 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L8 ANSWER 6 OF 11 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1999-542841 [46] WPIDS
CR 1994-265229 [33]
DNC C1999-158621
TI Treatment of female **infertility**, especially by in-vitro
fertilization.
DC B04
IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B
PA (ASTA) ASTA MEDICA AG
CYC 17
PI EP 947200 A2 19991006 (199946)* DE 5p
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
ADT EP 947200 A2 Div ex EP 1994-101672 19940204, EP 1999-102340 19940204
FDT EP 947200 A2 Div ex EP 611572
PRAI DE 1993-4305225 19930219
AB EP 947200 A UPAB: 19991110
NOVELTY - Sterile freeze-dried **cetrorelix** acetate (a peptide
described in EP299402) is used in the treatment of female
infertility.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
following: (1) use of sterile freeze-dried **cetrorelix** acetate
for protecting gonads against noxious agents that damage germ cells, e.g.
radiation treatment and chemotherapy; (2) a composition comprising
sterile
freeze-dried **cetrorelix** acetate and optionally excipients for
use in the treatment of female **infertility**; (3) a composition
comprising sterile freeze-dried **cetrorelix** acetate and
optionally excipients for protecting gonads against noxious agents that
damage germ cells, e.g. radiation treatment and chemotherapy with
cytostatic agents.
ACTIVITY - None given.
MECHANISM OF ACTION - Luteinizing hormone-releasing hormone (LHRH)
antagonist.
USE - In an in-vitro **fertilization** procedure in which
cetrorelix is administered to control the time of ovulation during
an ovary stimulation treatment by preventing a pre-ovulation increase in
luteinizing hormone (LH) levels, whereupon exogenous gonadotropin is
administered to induce ovulation after follicle maturation.
Dwg.0/0

L8 ANSWER 7 OF 11 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1994-265229 [33] WPIDS
DNC C1994-121294
TI Freeze-dried peptide compsns. - prep'd. by freeze drying soln. of peptide
in aq. acetic acid.
DC B04
IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B; BURKHARD, W;
JUERGEN, E
PA (ASTA) ASTA MEDICA AG
CYC 32
PI EP 611572 A2 19940824 (199433)* DE 5p
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DE 4305225 A1 19940825 (199433) 5p
AU 9455235 A 19940825 (199436)
NO 9400564 A 19940822 (199436)
CA 2115943 A 19940820 (199439)
CZ 9400312 A3 19940914 (199439)
BR 9400617 A 19940927 (199440)
SK 9400195 A3 19940907 (199440)
FI 9400779 A 19940820 (199441)
JP 06271476 A 19940927 (199443) 5p
ZA 9401136 A 19941026 (199444) 12p
HU 67117 T 19950228 (199514)
EP 611572 A3 19950111 (199538)

AU 671881 B 19960912 (199644)
 CN 1112019 A 19951122 (199737)
 SG 46632 A1 19980220 (199822)
 BR 1101004 A3 19980512 (199828)
 CZ 284314 B6 19981014 (199847)
 NZ 314707 A 19990225 (199914)
 CZ 285768 B6 19991117 (200002)
 EP 611572 B1 20000607 (200032) DE
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 DE 59409389 G 20000713 (200037)
 HU 218281 B 20000728 (200045)
 RU 2145234 C1 20000210 (200048)
 ES 2148247 T3 20001016 (200058)
 TW 387812 A 20000421 (200061)
 ADT EP 611572 A2 EP 1994-101672 19940204; DE 4305225 A1 DE 1993-4305225
 19930219; AU 9455235 A AU 1994-55235 19940217; NO 9400564 A NO 1994-564
 19940218; CA 2115943 A CA 1994-2115943 19940218; CZ 9400312 A3 CZ
 1994-312 19940214; BR 9400617 A BR 1994-617 19940218; SK 9400195 A3 SK 1994-195
 19940218; FI 9400779 A FI 1994-779 19940218; JP 06271476 A JP 1994-20532
 19940217; ZA 9401136 A ZA 1994-1136 19940218; HU 67117 T HU 1994-481
 19940218; EP 611572 A3 EP 1994-101672 19940204; AU 671881 B AU 1994-55235
 19940217; CN 1112019 A CN 1994-101378 19940218; SG 46632 A1 SG 1996-6874
 19940204; BR 1101004 A3 BR 1997-1101004 19970514; CZ 284314 B6 CZ
 1994-312 19940214; NZ 314707 A Div ex NZ 1994-250906 19940217, NZ 1994-314707
 19940217; CZ 285768 B6 CZ 1998-974 19940214; EP 611572 B1 EP 1994-101672
 19940204, Related to EP 1999-102340 19940204; DE 59409389 G DE
 1994-509389 19940204, EP 1994-101672 19940204; HU 218281 B HU 1994-481 19940218; RU
 2145234 C1 RU 1994-5001 19940218; ES 2148247 T3 EP 1994-101672 19940204;
 TW 387812 A TW 1994-100769 19940131
 FDT AU 671881 B Previous Publ. AU 9455235; CZ 284314 B6 Previous Publ. CZ
 9400312; NZ 314707 A Div ex NZ 250906; CZ 285768 B6 Previous Publ. CZ
 9800974; EP 611572 B1 Related to EP 947200; DE 59409389 G Based on EP
 611572; HU 218281 B Previous Publ. HU 67117; ES 2148247 T3 Based on EP
 611572
 PRAI DE 1993-4305225 19930219
 AB EP 611572 A UPAB: 19991110
 Freeze-dried compsns. comprising a peptide of 3-15 amino acid units and
 opt. one or more matrix materials are characterised in that 1 pt. wt. of
 the peptide is dissolved in 100-10,000 pts. wt. of acetic acid and then
 transferred to water and the resulting soln. is freeze dried.
 USE/ADVANTAGE - The compsns. esp. contain **cetrorelix** (EP
 299402), which is used in the treatment of female **infertility**
 (for controlling ovulation prior to isolating egg cells for in-vitro
 fertilisation) and for gonad protection in male patients (e.g.
 undergoing radio- or chemotherapy). The aq. acetic acid soln. can be
 sterilised by filtration without gelation or hydrolysis of the peptide.
 Dwg.0/0

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:725497 CAPLUS
 DN 133:261948
 TI Method for a programmed controlled ovarian stimulation protocol
 IN Engel, Jürgen; Riethmüller-Winzen, Hilde
 PA Asta Medica A.-G., Germany
 SO PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- ----- -----
 PI WO 2000059542 A1 20001012 WO 2000-EP2466 20000321

W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP,
KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR,
UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRAI US 1999-127241 P 19990331
US 1999-131632 P 19990428

AB A method of therapeutic management of **infertility** by programming of controlled ovarian stimulation (COS) and assisted reproductive procedures (ART) the improvement consisting of (a) suppression of premature ovulation with an LHRH-antagonist in controlled ovarian stimulation (COS) and assisted reproductive techniques (ART) with multiple follicle and oocyte development; (b) programming the start of controlled ovarian stimulation (COS) by the administration of progestogen only - or alternatively combined oral contraceptive preps.; (c) exogenous stimulation of the ovarian follicle growth; (d) ovulation induction with HCG, native LHRH, LHRH-agonists or recombinant LH; (e) application of assisted reprodn. techniques, esp. of IVF, ICSI, GIFT, ZIFT or by intrauterine insemination by sperm injection.

RE.CNT 6

RE

- (1) Albano, C; HUMAN REPRODUCTION 1996, V11/10(2114-2118)
- (2) Asta Medica Ag; EP 0788799 A 1997 CAPLUS
- (3) Asta Medica Ag; CA 2200541 A 1998 CAPLUS
- (4) Bouchard, P; OVULATION INDUCTION: UPDATE: THE PROCEEDINGS OF THE WORLD CONGRESS ON OVULATION INDUCTION 1998, P115 CAPLUS
- (5) Felberbaum, R; IN VITRO FERT ASSISTED REPROD, PROC WORLD CONGR 1997, P397 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2001 ACS

AN 1999:708625 CAPLUS

DN 131:295922

TI Method for the treatment of **fertility** disorders using an LHRH antagonist to partially suppress endogenous gonadotropins during intrauterine insemination

IN Engel, Jürgen; Riethmüller-Winzen, Hilde; Reissmann, Thomas

PA Asta Medica Aktiengesellschaft, Germany

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 9955357 | A1 | 19991104 | WO 1999-EP2133 | 19990329 |
| | W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP,
KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR,
UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE | | | | |

AU 9937028 A1 19991116 AU 1999-37028 19990329

BR 9909802 A 20001226 BR 1999-9802 19990329

EP 1082129 A1 20010314 EP 1999-919152 19990329

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

NO 2000005145 A 20001013 NO 2000-5145 20001013

PRAI US 1998-82743 P 19980423

WO 1999-EP2133 W 19990329

AB In the method of therapeutic management of **infertility** by intrauterine insemination the improvement consisting of (a) the dose-dependent suppression of endogenous gonadotropins, esp. LH, with a LH-RH Antagonist allowing the maintenance of physiol. estrogen levels,

(b)

exogenous stimulation of the ovarian follicle growth, (c) ovulation induction with HCG, native LHRH, LHRH-Agonists or recombinant LH, (d) intrauterine insemination by sperm injection. The LHRH Antagonists may

be preferably **Cetrorelix** or **Antarelix**. The stimulation is performed by administration of HMG or recombinant FSH with or without recombinant LH or with antiestrogens as for example Chlomiphene as well as with the combination of antiestrogens as for example Chlomiphene with gonadotropins.

RE.CNT 5

RE

- (1) Asta Medica AG; EP 0611572 A 1994 CAPLUS
- (2) Asta Medica AG; EP 0788799 A 1997 CAPLUS
- (3) Bouchard, P; Ovul Ind Update '98, Proc World Conf, 2nd 1998, P115 CAPLUS
- (4) Crowley, W; US 5130137 A 1992 CAPLUS
- (5) Schering AG; DE 19604231 A 1997 CAPLUS

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2001 ACS

AN 1999:538778 CAPLUS

DN 131:139954

TI LHRH antagonists in the treatment of **fertility** disorders

IN Bouchard, Philippe; Frydman, Rene; Diedrich, Klaus; **Engel, Juergen**; Devroey, Paul

PA Asta Medica AG, Germany

SO Can. Pat. Appl., 15 pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | CA 2200541 | AA | 19980722 | CA 1997-2200541 | 19970320 |
| PRAI | US 1997-786937 | | 19970122 | | |

AB A method of treating **infertility** disorders by administering an LH-RH antagonist, preferably **Cetrorelix**, in amts. to selectively suppress endogenous LH but not FSH secretion and inducing follicle growth by administration of exogenous gonadotropin. The selective suppression of

LH allows FSH secretion to be at natural levels thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual s.c. dose in the range of 1 mg to 10 mg, preferably 2 mg - 6 mg. In multiple dosing posol., LH-RH antagonist can be administered s.c. in an amt. in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addn. rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist

can be administered to avoid luteal phase stimulation by neutralizing the neg. effects of HCG:

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2001 ACS

AN 1998:672495 CAPLUS

DN 129:293891

TI Immobilized activity-stabilized LHRH antagonist complexes and their production

IN Engel, Juergen; Deger, Wolfgang; **Reissmann, Thomas**; Losse, Guenter; Naumann, Wolfgang; Murgas, Sandra

PA Asta Medica Aktiengesellschaft, Germany

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------------------|----------|
| PI | WO 9842381 | A1 | 19981001 | WO 1998-EP1398 | 19980311 |
| | W: AU, BR, CA, CN, CZ, HU, IL, JP, MX, NO, NZ, PL, RU, SK, TR, UA
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, | | | | |
| SE | DE 19712718 | A1 | 19981001 | DE 1997-19712718 | 19970326 |
| | DE 19712718 | C2 | 19990923 | | |
| | AU 9869207 | A1 | 19981020 | AU 1998-69207 | 19980311 |
| | BR 9807887 | A | 20000222 | BR 1998-7887 | 19980311 |
| | EP 981377 | A1 | 20000301 | EP 1998-914877 | 19980311 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, FI | | | IT, LI, LU, NL, SE, MC, PT, | |
| | US 6022860 | A | 20000208 | US 1998-48244 | 19980326 |
| | NO 9904665 | A | 19990924 | NO 1999-4665 | 19990924 |
| | US 6054555 | A | 20000425 | US 1999-422990 | 19991022 |
| PRAI | DE 1997-19712718 | | 19970326 | | |
| | WO 1998-EP1398 | | 19980311 | | |
| | US 1998-48244 | | 19980326 | | |
| AB | LHRH antagonists, esp. cetrorelix , are complexed with suitable biophilic carriers to enable sustained, targeted release of the active substance over a period of several weeks. The acidic polyamino acids, polyaspartic and polyglutamic acids, are selected for complexation with cetrorelix . The cetrorelix /polyamino acid complexes are produced from aq. solns. by combining the solns. and pptg. the complexes which are subsequently centrifuged off and vacuum dried over P2O5, preferably by lyophilization. These acidic polyamino acids display good sustained-release properties in a static liberation system depending on the hydrophobicity and molar mass of the polyamino acids. Animal testing demonstrated the efficacy of the cetrorelix /polyamino acid complexes as a depot system. By complexation of cetrorelix with polyamino acids, testosterone suppression can be achieved in male rats over a period of 600 h. Active substance release can thus be controlled according to polymer type and molar mass. | | | | |

=> s 16 and (infertil? or fertil?)

L9 17 L6 AND (INFERTIL? OR FERTIL?)

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 14 DUP REM L9 (3 DUPLICATES REMOVED)

=> s 110 and gonadotrophin?

L11 1 L10 AND GONADOTROPHIN?

=> d bib ab

L11 ANSWER 1 OF 1 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

AN 95280014 EMBASE

DN 1995280014

TI Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of **infertility**: An overview.

AU Reissmann Th.; Felberbaum R.; Diedrich K.; Engel J.; Comaru-Schally A.M.; Schally A.V.

CS ASTA Medica AG, Frankfurt-M, Germany

SO Human Reproduction, (1995) 10/8 (1974-1981).

ISSN: 0268-1161 CODEN: HUREEE

CY United Kingdom

DT Journal; Article
FS 003 Endocrinology
010 Obstetrics and Gynecology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB Luteinizing hormone-releasing hormone (LHRH) plays a crucial role in controlling the ovarian cycle in women. By modification of the molecular structure of this decapeptide, analogues were synthesized with agonistic or antagonistic effects on the gonadotrophic cells of the anterior pituitary gland. The agonists, after an initial stimulatory effect ('flare up'), lead to desensitization of the gonadotrophic cells and a reduction in the number of LHRH receptors on the cell membrane ('down-regulation'), while the antagonists produce an immediate effect by competitive blockade of the LHRH receptors. After administration of LHRH antagonists, the serum levels of FSH and LH decrease within hours. Nevertheless, the adenohypophysis maintains its responsiveness to an LHRH stimulus ('pituitary response') after pretreatment with an antagonist. This different pharmacological mechanism of LHRH antagonists makes possible new approaches to ovarian stimulation and to the therapy of sex steroid dependent diseases. The premature LH surge, the main cause of cancellation during induction of superovulation in assisted reproduction technology (ART) programmes, can be abolished by short term application of an LHRH antagonist associated with a reduced human menopausal gonadotrophin (hMG) requirement for ovarian stimulation. A future approach to ART might be based on the combination of pretreatment with an LHRH antagonist and ovulation induction by native LHRH or an agonist. The severe side effects encountered with early LHRH antagonists, such as anaphylactoid reactions due to histamine release, are almost completely eliminated in modern antagonists, especially **Cetrorelix** which is presently used clinically in controlled phase II clinical studies.

=> d 110 bib ab 1-15

L10 ANSWER 1 OF 14 USPATFULL
AN 2000:109312 USPATFULL
TI Diagnostic composition containing an LH-RH antagonist for hysteroscopy
IN Engel, Jürgen, Alzenau, Germany, Federal Republic of
Diedrich, Klaus, Gross-Sarau, Germany, Federal Republic of
Felberbaum, Ricardo, Lubeck, Germany, Federal Republic of
PA Asta Medica Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
corporation)
PI US 6106805 20000822
AI US 1997-961085 19971030 (8)
PRAI DE 1996-19644994 19961030
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Hartley, Michael
G.
LREP Cushman Darby & Cushman
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a diagnostic composition for improving the effectiveness of hysteroscopy, characterized in that it contains an LH-RH antagonist, in particular **cetrorelix**. The composition is

envisaged for use prior to hysteroscopy and/or for preparation for surgery, specifically in a single dose of between 0.1 and 2 mg/kg.

However, the composition can also be administered, for use prior to hysteroscopy and/or for preparation for surgery, in a multiple dose of between 0.01 and 0.5 mg/kg, preferably spread over 1-14 days. The composition is furthermore suitable for use in hysteroscopy in combination with the subsequent treatment of pathological conditions of the uterus such as myoma and endometrial hyperplasia.

L10 ANSWER 2 OF 14 USPATFULL
AN 2000:50805 USPATFULL
TI Process for the preparation of immobilized and activity-stabilized complexes of LHRH antagonists
IN Engel, Jurgen, Alzenau, Germany, Federal Republic of Deger, Wolfgang, Frankfurt, Germany, Federal Republic of Reissmann, Thomas, Frankfurt, Germany, Federal Republic of Losse, Gunter, Dresden, Germany, Federal Republic of Naumann, Wolfgang, Zug, Germany, Federal Republic of Murgas, Sandra, Dresden, Germany, Federal Republic of PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)
PI US 6054555 20000425
AI US 1999-422990 19991022 (9)
RLI Division of Ser. No. US 1998-48244, filed on 26 Mar 1998
PRAI DE 1997-19712718 19970326
DT Utility
FS Granted
EXNAM Primary Examiner: Moezie, F. T.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P._{sub.2}O._{sub.5} in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L10 ANSWER 3 OF 14 USPATFULL
AN 2000:15636 USPATFULL
TI Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation
IN Engel, Jurgen, Alzenau, Germany, Federal Republic of

Deger, Wolfgang, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
Losse, Gunter, Dresden, Germany, Federal Republic of
Naumann, Wolfgang, Zug, Germany, Federal Republic of
Murgas, Sandra, Dresden, Germany, Federal Republic of
PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)
PI US 6022860 20000208
AI US 1998-48244 19980326 (9)
PRAI DE 1997-19712718 19970326
DT Utility
FS Granted
EXNAM Primary Examiner: Moezie, F. T.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In this invention, a release-delaying system is to be developed for
LHRH antagonists, in particular for **cetrorelix**, which allows the
active compound to be released in a controlled manner over several
weeks by complexation with suitable biophilic carriers.

The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over

P.sub.2 0. sub.5 in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions.

In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid.

In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 2000:725497 CAPLUS
DN 133:261948
TI Method for a programmed controlled ovarian stimulation protocol
IN Engel, Jurgen; Riethmuller-winzen, Hilde
PA Asta Medica A.-G., Germany
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
----- ----- ----- -----
PI WO 2000059542 A1 20001012 WO 2000-EP2466 20000321
W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP,

KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR,
UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRAI US 1999-127241 P 19990331
US 1999-131632 P 19990428

AB A method of therapeutic management of **infertility** by programming of controlled ovarian stimulation (COS) and assisted reproductive procedures (ART) the improvement consisting of (a) suppression of premature ovulation with an LHRH-antagonist in controlled ovarian stimulation (COS) and assisted reproductive techniques (ART) with multiple follicle and oocyte development; (b) programming the start of controlled ovarian stimulation (COS) by the administration of progestogen only - or alternatively combined oral contraceptive preps.; (c) exogenous stimulation of the ovarian follicle growth; (d) ovulation induction with HCG, native LHRH, LHRH-agonists or recombinant LH; (e) application of assisted reprodn. techniques, esp. of IVF, ICSI, GIFT, ZIFT or by intrauterine insemination by sperm injection.

RE.CNT 6

RE

- (1) Albano, C; HUMAN REPRODUCTION 1996, V11/10(2114-2118)
- (2) Asta Medica Ag; EP 0788799 A 1997 CAPLUS
- (3) Asta Medica Ag; CA 2200541 A 1998 CAPLUS
- (4) Bouchard, P; OVULATION INDUCTION: UPDATE: THE PROCEEDINGS OF THE WORLDCONGRESS ON OVULATION INDUCTION 1998, P115 CAPLUS
- (5) Felberbaum, R; IN VITRO FERT ASSISTED REPROD, PROC WORLD CONGR 1997, P397 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-542841 [46] WPIDS

CR 1994-265229 [33]

DNC C1999-158621

TI Treatment of female **infertility**, especially by in-vitro fertilization.

DC B04

IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B
PA (ASTA) ASTA MEDICA AG

CYC 17

PI EP 947200 A2 19991006 (199946)* DE 5p

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

ADT EP 947200 A2 Div ex EP 1994-101672 19940204, EP 1999-102340 19940204

FDT EP 947200 A2 Div ex EP 611572

PRAI DE 1993-4305225 19930219

AB EP 947200 A UPAB: 19991110

NOVELTY - Sterile freeze-dried **cetrorelix** acetate (a peptide described in EP299402) is used in the treatment of female **infertility**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) use of sterile freeze-dried **cetrorelix** acetate for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy; (2) a composition comprising sterile

freeze-dried **cetrorelix** acetate and optionally excipients for use in the treatment of female **infertility**; (3) a composition comprising sterile freeze-dried **cetrorelix** acetate and optionally excipients for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy with cytostatic agents.

ACTIVITY - None given.

MECHANISM OF ACTION - Luteinizing hormone-releasing hormone (LHRH) antagonist.

USE - In an in-vitro **fertilization** procedure in which **cetrorelix** is administered to control the time of ovulation during

an ovary stimulation treatment by preventing a pre-ovulation increase in luteinizing hormone (LH) levels, whereupon exogenous gonadotropin is administered to induce ovulation after follicle maturation.
Dwg.0/0

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1999:708625 CAPLUS
DN 131:295922
TI Method for the treatment of **fertility** disorders using an LHRH antagonist to partially suppress endogenous gonadotropins during intrauterine insemination
IN Engel, Juergen; Riethmuller-Winzen, Hilde; Reissmann, Thomas
PA Asta Medica Aktiengesellschaft, Germany
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------|--|------|----------|-----------------|----------|
| PI | WO 9955357 | A1 | 19991104 | WO 1999-EP2133 | 19990329 |
| | W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9937028 | A1 | 19991116 | AU 1999-37028 | 19990329 |
| | BR 9909802 | A | 20001226 | BR 1999-9802 | 19990329 |
| | EP 1082129 | A1 | 20010314 | EP 1999-919152 | 19990329 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | NO 2000005145 | A | 20001013 | NO 2000-5145 | 20001013 |
| PRAI | US 1998-82743 | P | 19980423 | | |
| | WO 1999-EP2133 | W | 19990329 | | |
| AB | In the method of therapeutic management of infertility by intrauterine insemination the improvement consisting of (a) the dose-dependent suppression of endogenous gonadotropins, esp. LH, with a LHRH Antagonist allowing the maintenance of physiol. estrogen levels, | | | | |
| (b) | exogenous stimulation of the ovarian follicle growth, (c) ovulation induction with HCG, native LHRH, LHRH-Agonists or recombinant LH, (d) intrauterine insemination by sperm injection. The LHRH Antagonists may be preferably Cetrorelix or Antarelix. The stimulation is performed by administration of HMG or recombinant FSH with or without recombinant LH or with antiestrogens as for example Chlomiphene as well as with the combination of antiestrogens as for example Chlomiphene with gonadotropins. | | | | |
| RE.CNT 5 | | | | | |
| RE | | | | | |
| (1) | Asta Medica AG; EP 0611572 A 1994 CAPLUS | | | | |
| (2) | Asta Medica AG; EP 0788799 A 1997 CAPLUS | | | | |
| (3) | Bouchard, P; Ovul Ind Update '98, Proc World Conf, 2nd 1998, P115 CAPLUS | | | | |
| (4) | Crowley, W; US 5130137 A 1992 CAPLUS | | | | |
| (5) | Schering AG; DE 19604231 A 1997 CAPLUS | | | | |

PA Asta Medica Aktiengesellschaft, Germany
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9842381 | A1 | 19981001 | WO 1998-EP1398 | 19980311 |
| | W: AU, BR, CA, CN, CZ, HU, IL, JP, MX, NO, NZ, PL, RU, SK, TR, UA
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, | | | | |
| SE | DE 19712718 | A1 | 19981001 | DE 1997-19712718 | 19970326 |
| | DE 19712718 | C2 | 19990923 | | |
| | AU 9869207 | A1 | 19981020 | AU 1998-69207 | 19980311 |
| | BR 9807887 | A | 20000222 | BR 1998-7887 | 19980311 |
| | EP 981377 | A1 | 20000301 | EP 1998-914877 | 19980311 |
| | R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, LI, LU, NL, MC, PT,
IE, FI | | | | |
| | US 6022860 | A | 20000208 | US 1998-48244 | 19980326 |
| | NO 9904665 | A | 19990924 | NO 1999-4665 | 19990924 |
| | US 6054555 | A | 20000425 | US 1999-422990 | 19991022 |
| PRAI | DE 1997-19712718 | | 19970326 | | |
| | WO 1998-EP1398 | | 19980311 | | |
| | US 1998-48244 | | 19980326 | | |
| AB | LHRH antagonists, esp. cetrorelix , are complexed with suitable biophilic carriers to enable sustained, targeted release of the active substance over a period of several weeks. The acidic polyamino acids, polyaspartic and polyglutamic acids, are selected for complexation with cetrorelix . The cetrorelix /polyamino acid complexes are produced from aq. solns. by combining the solns. and pptg. the complexes which are subsequently centrifuged off and vacuum dried over P2O5, preferably by lyophilization. These acidic polyamino acids display good sustained-release properties in a static liberation system depending on the hydrophobicity and molar mass of the polyamino acids. Animal testing demonstrated the efficacy of the cetrorelix /polyamino acid complexes as a depot system. By complexation of cetrorelix with polyamino acids, testosterone suppression can be achieved in male rats over a period of 600 h. Active substance release can thus be controlled according to polymer type and molar mass. | | | | |

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:538778 CAPLUS
 DN 131:139954
 TI LHRH antagonists in the treatment of **fertility** disorders
 IN Bouchard, Philippe; Frydman, Rene; Diedrich, Klaus; Engel, Jurgen
 ; Devroey, Paul
 PA Asta Medica AG, Germany
 SO Can. Pat. Appl., 15 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | CA 2200541 | AA | 19980722 | CA 1997-2200541 | 19970320 |
| PRAI | US 1997-786937 | | 19970122 | | |
| AB | A method of treating infertility disorders by administering an LH-RH antagonist, preferably Cetrorelix , in amts. to selectively suppress endogenous LH but not FSH secretion and inducing follicle growth by administration of exogenous gonadotropin. The selective suppression of LH allows FSH secretion to be at natural levels thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual s.c. dose in the range of 1 mg to 10 mg, preferably 2 mg - | | | | |

6 mg. In multiple dosing posol., LH-RH antagonist can be administered s.c. in an amt. in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addn. rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the neg. effects of HCG.

L10 ANSWER 9 OF 14 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1998:409001 BIOSIS
DN PREV199800409001
TI The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist **cetrorelix**.
AU Albano, Carola (1); Grimbizis, Grigoris; Smitz, Johan;
Riethmueller-Winzen, Hilde; Reissmann, Thomas; Van Steirteghem,
Andre; Devroey, Paul
CS (1) Centre Reproductive Med., Brussels Free Univ., Laarbeeklaan 101, 1090
Brussels Belgium
SO Fertility and Sterility, (Aug., 1998) Vol. 70, No. 2, pp. 357-359.
ISSN: 0015-0282.
DT Article
LA English
AB Objective: To analyze the luteal phase of six patients undergoing controlled ovarian hyperstimulation (COH) with hMG and a new GnRH antagonist, **Cetrorelix**, without receiving luteal phase supplementation. Design: Phase II study involving the first six patients who did not receive luteal phase support. Setting: Tertiary referral center. Patient(s): Six healthy women undergoing COH for assisted reproductive techniques. Intervention(s): Oocyte retrieval was performed 36 hours after hCG administration, followed by embryo transfer 2 days later. No luteal phase supplementation was given. Main Outcome Measure(s): Serum E2, progesterone, LH, and FSH concentrations were measured. Result(s): The length of the luteal phase was \leq 12 days in three of the six patients. One of the patients in whom the luteal phase was >12 days had a low serum progesterone concentration (2.9 ng/mL) on day 10. Serum LH concentrations decreased after the preovulatory hCG injection in all patients. However, a progressive increase in LH was observed after day 7, reaching normal values. Conclusion(s): Corpus luteum function seems to be impaired in cycles that are stimulated with hMG and the GnRH antagonist **Cetrorelix**.

L10 ANSWER 10 OF 14 USPATFULL
AN 97:78416 USPATFULL
TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases
IN Engel, Jurgen, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)
PI US 5663145 19970902
AI US 1994-354838 19941208 (8)
PRAI DE 1993-4342091 19931209
DT Utility
FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 7

DRWN No Drawings

LN.CNT 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L10 ANSWER 11 OF 14 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 1

AN 95280014 EMBASE

DN 1995280014

TI Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of **infertility**: An overview.

AU Reissmann Th.; Felberbaum R.; Diedrich K.; Engel J.; Comaru-Schally A.M.; Schally A.V.

CS ASTA Medica AG, Frankfurt-M, Germany

SO Human Reproduction, (1995) 10/8 (1974-1981).

ISSN: 0268-1161 CODEN: HUREEE

CY United Kingdom

DT Journal; Article

FS 003 Endocrinology

010 Obstetrics and Gynecology

037 Drug Literature Index

038 Adverse Reactions Titles

LA English

SL English

AB Luteinizing hormone-releasing hormone (LHRH) plays a crucial role in controlling the ovarian cycle in women. By modification of the molecular structure of this decapeptide, analogues were synthesized with agonistic or antagonistic effects on the gonadotrophic cells of the anterior pituitary gland. The agonists, after an initial stimulatory effect

('flare

up'), lead to desensitization of the gonadotrophic cells and a reduction in the number of LHRH receptors on the cell membrane ('down-regulation'), while the antagonists produce an immediate effect by competitive blockade of the LHRH receptors. After administration of LHRH antagonists, the

serum

levels of FSH and LH decrease within hours. Nevertheless, the adenohypophysis maintains its responsiveness to an LHRH stimulus ('pituitary response') after pretreatment with an antagonist. This different pharmacological mechanism of LHRH antagonists makes possible

new

approaches to ovarian stimulation and to the therapy of sex steroid dependent diseases. The premature LH surge, the main cause of cancellation

during induction of superovulation in assisted reproduction technology (ART) programmes, can be abolished by short term application of an LHRH antagonist associated with a reduced human menopausal gonadotrophin (HMG) requirement for ovarian stimulation. A future approach to ART might be based on the combination of pretreatment with an LHRH antagonist and ovulation induction by native LHRH or an agonist. The severe side effects encountered with early LHRH antagonists, such as anaphylactoid reactions due to histamine release, are almost completely eliminated in modern antagonists, especially **Cetrorelix** which is presently used clinically in controlled phase II clinical studies.

L10 ANSWER 12 OF 14 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2

AN 1995:415178 BIOSIS

DN PREV199598429478

TI Preserved pituitary response under ovarian stimulation with HMG and GnRH

antagonists (**Cetrorelix**) in women with tubal infertility

AU Felberbaum, Ricardo E. (1); Reissmann, Thomas; Kuepker, Wolfgang; Bauer, Otmar; Al Hasani, Safaa; Diedrich, Christa; Diedrich, Klaus
CS (1) Dep. of Obstetrics and Gynecology, Medical Univ. of Luebeck, Luebeck
Germany

SO European Journal of Obstetrics & Gynecology and Reproductive Biology,
(1995) Vol. 61, No. 2, pp. 151-155.
ISSN: 0301-2115.

DT Article

LA English

AB Objective: To examine the pituitary response in patients undergoing short-term application of the GnRH antagonist **Cetrorelix** in the mid-cycle phase for hypophysial suppression of premature LH surges within an IVF-program. Design: Twenty patients suffering from primary or secondary tubal infertility were stimulated with hMG from cycle day 2. From day 7 till ovulation induction **Cetrorelix** was administered in two different dose regimens (15 patients 3 mg s.c. daily; 5 patients 1 mg s.c. daily). Three hours before ovulation induction a

GnRH test was performed using 25 mu-g of native GnRH and the pituitary response

examined by measurement of the serum LH concentration after 30 min.

Results: Premature LH surges could be avoided in the 3-mg group and in the 1-mg group, respectively. Due to this, none of the cycles had to be cancelled. Oestradiol profiles and ultrasound demonstrated a satisfactory follicular maturation. All patients showed pronounced suppression of the serum LH levels before ovulation induction. The mean increase of serum LH due to the performed GnRH test was 10 mIU/ml for the 3-mg group, while

the average maximum in the 1-mg group was about 32.5 mIU/ml. Conclusions: The pituitary response is preserved by the treatment with the GnRH antagonist **Cetrorelix**. The extent of suppression of the adenohypophysis, as expressed by the different reactions on GnRH test, can be modulated by the

dosage administered. This should allow ovulation induction by GnRH or one of its agonists instead of hCG, which could be beneficial in patients at high risk of Ovarian Hyperstimulation Syndrome (OHSS) and those suffering from Polycystic Ovary Disease (PCOD).

L10 ANSWER 13 OF 14 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

DUPLICATE

3

AN 1994-265229 [33] WPIDS

DNC C1994-121294

TI Freeze-dried peptide compsns. - prep'd. by freeze drying soln. of peptide in aq. acetic acid.

DC B04

IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B; BURKHARD, W;
JUERGEN, E

PA (ASTA) ASTA MEDICA AG

CYC 32

PI EP 611572 A2 19940824 (199433)* DE 5p

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE 4305225 A1 19940825 (199433) 5p

AU 9455235 A 19940825 (199436)

NO 9400564 A 19940822 (199436)

CA 2115943 A 19940820 (199439)

CZ 9400312 A3 19940914 (199439)

BR 9400617 A 19940927 (199440)

SK 9400195 A3 19940907 (199440)

FI 9400779 A 19940820 (199441)

JP 06271476 A 19940927 (199443) 5p

ZA 9401136 A 19941026 (199444) 12p
 HU 67117 T 19950228 (199514)
 EP 611572 A3 19950111 (199538)
 AU 671881 B 19960912 (199644)
 CN 1112019 A 19951122 (199737)
 SG 46632 A1 19980220 (199822)
 BR 1101004 A3 19980512 (199828)
 CZ 284314 B6 19981014 (199847)
 NZ 314707 A 19990225 (199914)
 CZ 285768 B6 19991117 (200002)
 EP 611572 B1 20000607 (200032) DE
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 DE 59409389 G 20000713 (200037)
 HU 218281 B 20000728 (200045)
 RU 2145234 C1 20000210 (200048)
 ES 2148247 T3 20001016 (200058)
 TW 387812 A 20000421 (200061)
 ADT EP 611572 A2 EP 1994-101672 19940204; DE 4305225 A1 DE 1993-4305225
 19930219; AU 9455235 A AU 1994-55235 19940217; NO 9400564 A NO 1994-564
 19940218; CA 2115943 A CA 1994-2115943 19940218; CZ 9400312 A3 CZ
 1994-312
 19940214; BR 9400617 A BR 1994-617 19940218; SK 9400195 A3 SK 1994-195
 19940218; FI 9400779 A FI 1994-779 19940218; JP 06271476 A JP 1994-20532
 19940217; ZA 9401136 A ZA 1994-1136 19940218; HU 67117 T HU 1994-481
 19940218; EP 611572 A3 EP 1994-101672 19940204; AU 671881 B AU 1994-55235
 19940217; CN 1112019 A CN 1994-101378 19940218; SG 46632 A1 SG 1996-6874
 19940204; BR 1101004 A3 BR 1997-1101004 19970514; CZ 284314 B6 CZ
 1994-312
 19940214; NZ 314707 A Div ex NZ 1994-250906 19940217, NZ 1994-314707
 19940217; CZ 285768 B6 CZ 1998-974 19940214; EP 611572 B1 EP 1994-101672
 19940204, Related to EP 1999-102340 19940204; DE 59409389 G DE
 1994-509389
 19940204, EP 1994-101672 19940204; HU 218281 B HU 1994-481 19940218; RU
 2145234 C1 RU 1994-5001 19940218; ES 2148247 T3 EP 1994-101672 19940204;
 TW 387812 A TW 1994-100769 19940131
 FDT AU 671881 B Previous Publ. AU 9455235; CZ 284314 B6 Previous Publ. CZ
 9400312; NZ 314707 A Div ex NZ 250906; CZ 285768 B6 Previous Publ. CZ
 9800974; EP 611572 B1 Related to EP 947200; DE 59409389 G Based on EP
 611572; HU 218281 B Previous Publ. HU 67117; ES 2148247 T3 Based on EP
 611572
 PRAI DE 1993-4305225 19930219
 AB EP 611572 A UPAB: 19991110
 Freeze-dried compsns. comprising a peptide of 3-15 amino acid units and
 opt. one or more matrix materials are characterised in that 1 pt. wt. of
 the peptide is dissolved in 100-10,000 pts. wt. of acetic acid and then
 transferred to water and the resulting soln. is freeze dried.
 USE/ADVANTAGE - The compsns. esp. contain **cetrorelix** (EP
 299402), which is used in the treatment of female **infertility**
 (for controlling ovulation prior to isolating egg cells for **in-vitro**
 fertilisation) and for gonad protection in male patients (e.g.
 undergoing radio- or chemotherapy). The aq. acetic acid soln. can be
 sterilised by filtration without gelation or hydrolysis of the peptide.
 Dwg.0/0
 L10 ANSWER 14 OF 14 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
 AN 94179320 EMBASE
 DN 1994179320
 TI Introduction of LHRH-antagonists into the treatment of gynaecological
 disorders.
 AU Reissmann Th.; Diedrich K.; Comaru-Schally A.M.; Schally A.V.
 CS Clinic Obstetrics and Gynaecology, University of Lubeck, Lubeck, Germany
 SO Human Reproduction, (1994) 9/5 (767-769).
 ISSN: 0268-1161 CODEN: HUREEE
 CY United Kingdom
 DT Journal; (Short Survey)

FS 010 Obstetrics and Gynecology
021 Developmental Biology and Teratology
030 Pharmacology
037 Drug Literature Index
LA English

=> s infertil? or fertil?

L12 687340 INFERTIL? OR FERTIL?

=> s l12 and cetrorelix

L13 229 L12 AND CETRORELIX

=> s l13 and (female or gonadotrpohin)

L14 141 L13 AND (FEMALE OR GONADOTRPOHIN)

=>

=>

=>

=>

=>

=>

=>

=>

YOU HAVE RECEIVED 8 CONSECUTIVE ARROW PROMPTS (>)

The arrow (>) is the system prompt, where you enter a command. For an explanation of system commands, files, formats, etc., enter "HELP" and the name of the item you want explained at an arrow prompt (>). Enter "HELP COMMANDS" for a list of commands that can be used in this file. Enter "HELP MESSAGES" for a list of online explanations that are available. The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message. Enter "HELP" or "?" at a prompt to see an explanation of the options. After an error message, enter "HELP" or "?" at the next prompt and you will receive a more detailed explanation of the error and how to correct it.

Automatic help is also available. When AUHELP is 'ON', you will automatically receive help following an error message. For more information on AUHELP, enter "HELP SET AUHELP" at an arrow prompt (>).

Users who need additional assistance can contact the Help Desk at their nearest STN Service Center. Enter "HELP STN" for information on STN Service Centers. You may also choose to contact the database representative for the file you are searching, for more detailed help on database content and search strategy. For information on how to contact database representatives for the current file, enter "HELP DESK" at an arrow prompt (>).

IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
=>

=>

=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=>
=> d his

(FILE 'HOME' ENTERED AT 12:32:54 ON 17 JUL 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,
AGRICOLA,
LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:33:40 ON 17 JUL 2001
E ENGEL JURGEN/AU

L1 209 S E3-E4
E WICHERT BURKHARD/AU

L2 12 S E3-E4
E SAUERBIAR DEITER/AU
E SAUERBIER DEITER/AU

L3 42 S E2-E5
E REISSMANN THOMAS/AU

L4 54 S E1-E4

L5 284 S L1-L4

L6 52 S L5 AND CETRORELIX

L7 38 DUP REM L6 (14 DUPLICATES REMOVED)

L8 11 S L7 AND (INFERTIL? OR FERTILI?)

L9 17 S L6 AND (INFERTIL? OR FERTIL?)

L10 14 DUP REM L9 (3 DUPLICATES REMOVED)

L11 1 S L10 AND GONADOTROPHIN?

L12 687340 S INFERTIL? OR FERTIL?

L13 229 S L12 AND CETRORELIX

L14 141 S L13 AND (FEMALE OR GONADOTRPOHIN)

=> s l13 and (female or gonadotrophin)

L15 165 L13 AND (FEMALE OR GONADOTROPHIN)

=> s 115 and hmg

L16 61 L15 AND HMG

=> dup rem 116

PROCESSING COMPLETED FOR L16

L17 27 DUP REM L16 (34 DUPLICATES REMOVED)

=> d bib ab 1-27

L17 ANSWER 1 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 1
AN 2001139783 EMBASE
TI Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with **HMG** alone or in association with the GnRH antagonist **Cetrorelix**.
AU Tavaniotou A.; Albano C.; Smitz J.; Devroey P.
CS P. Devroey, AZ-VUB, Centre for Reproductive Medicine, Laarbeeklaan 101, 1090 Brussels, Belgium. paul.devroey@az.vub.ac.be
SO Human Reproduction, (2001) 16/4 (663-667).
Refs: 36
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 010 Obstetrics and Gynecology
003 Endocrinology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
AB Luteinizing hormone (LH) is mandatory for the maintenance of the corpus luteum. Ovarian stimulation for IVF has been associated with a defective luteal phase. The luteal phases of two groups of patients with normal menstrual cycles and no endocrinological cause of **infertility** were retrospectively analysed in IVF cycles. Thirty-one **infertile** patients stimulated with human menopausal gonadotrophins (**HMG**) for IVF to whom the **gonadotrophin**-releasing hormone (GnRH) antagonist **Cetrorelix** 0.25 mg was also administered to prevent the LH surge (group I) were compared with 31 **infertile** patients stimulated with **HMG** alone (group II). Despite differences in the stimulation outcome, luteal LH serum concentrations were similar in the two groups. LH values dropped from 2.3 .+- . 1 IU/I on the day of human chorionic **gonadotrophin** (HCG) administration to 1.1 .+- . 0.7 IU/I on day HCG + 2 in group I ($P < 0.0001$) and from 5.1 .+- . 3 to 1.2 .+- . 1.7 IU/I ($P < 0.0001$) in group II. In the mid-luteal phase, LH concentrations were low in both groups. Our results suggest that suppressed LH concentrations in the early and mid-luteal phase may not be attributed solely to the GnRH-antagonist administration. Pituitary LH secretion may be inhibited by supraphysiological steroid serum concentration via long-loop feedback and/or by the central action of the exogenously administered HCG via a short-loop mechanism.

L17 ANSWER 2 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

AN 2001030138 EMBASE

TI The use of LHRH antagonist: Multiple-dose administration.

AU Ludwig M.; Felberbaum R.E.; Diedrich K.

CS Dr. R.E. Felberbaum, Dept. of Gynecology and Obstetrics, Medical University of Lubeck, Razteburger Allee 160, 23562 Lubeck, Germany

SO Infertility and Reproductive Medicine Clinics of North America, (2001) 12/1 (129-139).

Refs: 25

ISSN: 1047-9422 CODEN: IRMCF8

CY United States

DT Journal; General Review

FS 003 Endocrinology

010 Obstetrics and Gynecology

037 Drug Literature Index

038 Adverse Reactions Titles

LA English

SL English

AB The multiple-dose antagonist protocol for ovarian stimulation in IVF cycles can be combined with hMG or recombinant FSH. The protocol has several advantages, such as a reduction in the rate of moderate-to-severe OHSS, a shorter stimulation period, and more comfort for patients. There are no hormonal withdrawal symptoms, and a spontaneous

menstrual cycle can be used. Whether there is a reduced pregnancy rate in this protocol when compared with the long agonist protocol is still a matter of debate. A significant difference has not been shown in any study

thus far. A possible effect of the antagonist on endometrial receptivity has been suggested. Experimental data and prospective studies must be awaited before this hypothesis can be proven.

L17 ANSWER 3 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

AN 2001030137 EMBASE

TI GnRH antagonist in single-dose applications.

AU Olivennes F.; Fanchin R.; Rongieres-Bertrand C.; Bouchard P.; Frydman R.

CS Dr. F. Olivennes, Dept. of Obstetrics and Gynecology, A. Beclere Hospital,

157, Rue de la Porte de Trivaux, 92140 Clamart Cedex, France

SO Infertility and Reproductive Medicine Clinics of North America, (2001) 12/1 (119-128).

Refs: 27

ISSN: 1047-9422 CODEN: IRMCF8

CY United States

DT Journal; General Review

FS 003 Endocrinology

010 Obstetrics and Gynecology

036 Health Policy, Economics and Management

037 Drug Literature Index

038 Adverse Reactions Titles

LA English

SL English

AB Use of the GnRH antagonist **Cetrorelix** in natural cycles associated with gonadotropins allowed the authors to reduce the rate of premature and endogenous LH surges and, subsequently, the cancellation rate. Stimulation was minimal, and the pregnancy rates in this preliminary

report were satisfactory. If a larger study confirms the results of the natural cycle with hMG support, the association of spontaneous cycles and the GnRH antagonist single-dose administration could represent in selected indications a promising first-choice IVF treatment regimen, avoiding the complications and the risks of the ovarian stimulation protocols. The reduction of the cost and the benefit of the oocyte retrieval in an outpatient procedure are obvious. Successive cycles with an acceptable success rate could result in increased cumulative pregnancy rates. In controlled ovarian stimulation, different studies have confirmed

the efficacy of a single dose of 3 mg of **Cetrorelix** to prevent premature LH surges when administered in the late follicular phase. The single-dose protocol is easy to use and ensures the patient's compliance. When compared with the long protocol using a depot formula of triptorelin,

the IVF-ET results showed a shorter duration of treatment, less amount of hMG needed, and a lower occurrence of ovarian hyperstimulation

syndrome. The tolerance to **Cetrorelix** was excellent in all of the patients treated, with only mild and transitory reactions at the injection site. GnRH antagonists are already available for clinical use in

some countries. These compounds are expected to change protocols of ovarian stimulation. If similar pregnancy rates are confirmed, the main advantage of these compounds will be the reduction of side effects and complication rates. They could also allow the design of softer stimulation

protocols using clomiphene citrate and "natural cycles." GnRH antagonists will enable different ways of triggering ovulation with native GnRH and GnRH agonists.

L17 ANSWER 4 OF 27 MEDLINE

AN 2000482969 MEDLINE

DN 20425014 PubMed ID: 10966979

TI Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor.

AU Mannaerts B; Gordon K

CS Organon, Oss, The Netherlands.. b.mannerts@organon.oss.akzonobel.nl

SO HUMAN REPRODUCTION, (2000 Sep) 15 (9) 1882-3.

Journal code: HRP; 8701199. ISSN: 0268-1161.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200010

ED Entered STN: 20001019

Last Updated on STN: 20001019

Entered Medline: 20001010

AB Recent suggestions that **gonadotrophin**-releasing hormone (GnRH) antagonists activate the GnRH receptor are discussed. Most of the studies cited in support of this suggestion are in-vitro studies, testing supra-pharmacological doses of GnRH analogues in cancer cell lines, whereas GnRH antagonists, e.g. ganirelix or **cetrorelix**, do not affect the steroidogenesis of human granulosa cells in vitro. In patients treated with GnRH antagonists prior to IVF or intracytoplasmic sperm injection (ICSI), oocyte maturity and fertilization rates are equal to those achieved following a long protocol of GnRH agonists. Although there is a tendency towards a lower pregnancy rate (not statistically significant) in the initial trials using GnRH antagonist with either recombinant FSH or human menopausal **gonadotrophin** (**HMG**) for ovarian stimulation, this new treatment option of GnRH antagonists facilitates short and simple treatment and improves the convenience and safety for the patient. As with GnRH agonists in the past,

the clinical outcome of GnRH antagonist treatment will improve with time as more clinical experience is gained (learning curve) and the treatment protocol is optimized. Moreover, a GnRH agonist instead of human chorionic

gonadotrophin (HCG) may be used for triggering ovulation and will decrease the cancellation rate and minimize the risk for developing ovarian hyperstimulation syndrome (OHSS).

L17 ANSWER 5 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 2

AN 2000164435 EMBASE

TI Ovarian stimulation for assisted reproduction with **HMG** and concomitant midcycle administration of the GnRH antagonist **Cetrorelix** according to the multiple dose protocol: A prospective uncontrolled phase III study.

AU Felberbaum R.E.; Albano C.; Ludwig M.; Riethmuller-Winzen H.; Grigat M.; Devroey P.; Diedrich K.H.R.

CS Dr. R.E. Felberbaum, Dept. of Obstetrics and Gynaecology, Medical University of Lubeck, Lubeck, Germany

SO Human Reproduction, (2000) 15/5 (1015-1020).
Refs: 28
ISSN: 0268-1161 CODEN: HUREEE

CY United Kingdom
DT Journal; Article
FS 037 Drug Literature Index
010 Obstetrics and Gynecology
003 Endocrinology
038 Adverse Reactions Titles

LA English
SL English

AB A total of 346 women with normal ovulatory function was stimulated with human menopausal gonadotrophins (**HMG**) to attain ovarian stimulation for IVF or intracytoplasmic sperm injection (ICSI). Stimulation with **HMG** started on cycle day 2 or 3. After 6 days of stimulation, **Cetrorelix** in its minimum effective multiple dose of 0.25 mg/day, was administered daily until induction of ovulation. In total, 333 patients (96.2%) reached the day of HCG administration, and 324 (93.6%) underwent oocyte retrieval. A mean of 25.2 ampoules of **HMG** was applied for a mean of 10.4 days. **Cetrorelix** was administered for a mean time lapse of 5.7 days. The mean normal **fertilization** rate was 60% in the IVF group and 59% in the ICSI group. Seventy pregnancies were attained, reflecting an ongoing clinical pregnancy rate of 24% per transfer. The ongoing clinical implantation rate was 11.4%. Only three cases of raised luteinizing hormone (LH) (.gtoreq.10 IU/l) with increased progesterone secretion (.gtoreq.1 ng/ml) were observed after initiation of **Cetrorelix** administration, reflecting an incidence of premature luteinization of 0.9%. The abortion rate was 17%. The incidence of severe ovarian hyperstimulation syndrome (World Health Organization grade III) was as low as 0.6%.

L17 ANSWER 6 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 3
AN 2000095892 EMBASE

TI Ovarian stimulation with **HMG**: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist **cetrorelix** and the LHRH-agonist buserelin.

AU Albano C.; Felberbaum R.E.; Smits J.; Riethmuller-Winzen H.; Engel J.; Diedrich K.; Devroey P.

CS Dr. C. Albano, Centre for Reproductive Medicine, Dutch-speaking Brussels Free Univ., Brussels, Belgium

SO Human Reproduction, (2000) 15/3 (526-531).
Refs: 22
ISSN: 0268-1161 CODEN: HUREEE

CY United Kingdom
DT Journal; Article
FS 010 Obstetrics and Gynecology
037 Drug Literature Index

LA English
SL English

AB In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist **cetrorelix**, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro **fertilization** (IVF)/intracytoplasmic sperm injection (ICSI) cycles. Ultimately, 181 patients (96.3%) in the **cetrorelix** group, and 77 (90.6%) in the buserelin group, reached the day of the human chorionic gonadotrophin (HCG) injection. The mean number of human menopausal gonadotrophin (**HMG**) ampoules administered and the mean number of stimulation days with **HMG** were significantly less in the **cetrorelix** group than in the buserelin group ($P < 0.01$). A rise in LH and progesterone concentrations

was observed in three of the 188 patients (1.6%) who received **cetrorelix**. On the day of the HCG administration, more follicles of a small diameter (11-14 mm) were observed in the buserelin group than in the **cetrorelix** group ($P = 0.02$) and the mean serum oestradiol concentration was significantly higher in patients who received buserelin than in those who received **cetrorelix** ($P < 0.01$). Similar results were observed in **fertilization**, cleavage and pregnancy rates in the two groups. In conclusion, the use of the LHRH antagonists might be considered more advantageous because of the short-term application needed to inhibit **gonadotrophin** secretion, so allowing a reduction in the treatment time in a clinically significant manner.

L17 ANSWER 7 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 4
AN 2000041165 EMBASE
TI Prospective, randomized, controlled study of in vitro **fertilization**-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (**cetrorelix**) or a depot formula of an LH-RH agonist (triptorelin).
AU Olivennes F.; Belaisch-Allart J.; Emperaire J.C.; Dechaud H.; Alvarez S.; Moreau L.; Nicollet B.; Zorn J.R.; Bouchard P.; Frydman R.
CS Dr. F. Olivennes, Service Gynecologie-Obstetrique, Hopital A. Beclere,
157 Rue de la Porte De Trivaux, 92140 Clamart Cedex, France
SO Fertility and Sterility, (2000) 73/2 (314-320).
Refs: 22
ISSN: 0015-0282 CODEN: FESTAS
PUI S 0015-0282(99)00524-5
CY United States
DT Journal; Article
FS 010 Obstetrics and Gynecology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB Objective: To confirm the value of a single dose of 3 mg of **cetrorelix** in preventing the occurrence of premature LH surges. Design: Multicenter randomized, prospective study. Setting: Reproductive medicine units. Patient(s): **Infertile** patients undergoing ovarian stimulation for IVF-ET. Intervention(s): A single dose of 3 mg of **cetrorelix** (Cetrotide; ASTA Medica, Frankfurt, Germany) (115 patients) was administered in the late follicular phase. A depot preparation of triptorelin (Decapeptyl; Ipsen-Biotech, Paris, France) was chosen as a control agent (39 patients). Ovarian stimulation was conducted with hMG (Menogon; Ferring, Kiel, Germany). Main Outcome Measure(s): Premature LH surges (LH level >10 IU/L), progesterone level greater than 1 ng/L, and IVF results. Result(s): No LH surge occurred after **cetrorelix** administration. The patients in the **cetrorelix** group had a lower number of oocytes and embryos. The percentage of mature oocytes and **fertilization** rates were similar in both groups, and the pregnancy rates were not statistically different. The length of stimulation, number of hMG ampules administered, and occurrence of the ovarian hyperstimulation syndrome were lower in the **cetrorelix** group. Tolerance of **cetrorelix** was excellent. Conclusion(s): A **cetrorelix** single-dose protocol prevented LH surges in all patients studied. It compares favorably to the 'long protocol' and could be a protocol of choice in IVF-ET. Copyright (C) 2000 American Society for Reproductive Medicine.
L17 ANSWER 8 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 5
AN 2000302500 EMBASE

TI GnRH antagonist in single-dose applications.
AU Olivennes F.; Ayoubi J.M.; Fanchin R.; Rongieres-Bertrand C.; Hamamah S.;
Bouchard P.; Frydman R.
CS F. Olivennes, Department of Obstetrics/Gynecology, A. Beclere Hopital,
157 Rue de la Porte de Trivaux, 92140 Clamart cedex, France
SO Human Reproduction Update, (2000) 6/4 (313-317).
Refs: 21
ISSN: 1355-4786 CODEN: HRUPF8
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
010 Obstetrics and Gynecology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB Previous studies on ovarian stimulation have confirmed the efficacy of a single dose of the gonadotrophin-releasing hormone (GnRH) antagonist, **Cetrorelix**, in preventing premature LH surges. The single-dose protocol is easy to use and assures patient compliance. When compared with the long protocol using a depot administration of the GnRH agonist, triptorelin, the IVF results in patients treated with **Cetrorelix** showed a shorter treatment duration, reduced amount of human menopausal gonadotrophin (HMG) required and a lower occurrence of ovarian hyperstimulation syndrome (OHSS). The pregnancy rates did not differ significantly between the two treatments. The use of **Cetrorelix** in natural cycles associated with gonadotrophins reduced the rate of premature LH surges and, therefore, the cancellation rate. The stimulation was minimal and the preliminary pregnancy rates were satisfactory. If a larger study confirms the results of the natural cycle with HMG support, the single-dose administration of GnRH antagonist could represent an interesting first-choice IVF treatment in selected indications. The tolerance of **Cetrorelix** was excellent in all patients, with only mild and transitory reactions at the injection site. New GnRH antagonists are already available for clinical use in some countries, and they will certainly change ovarian stimulation protocols. If the pregnancy rates are confirmed, the main advantages of these new compounds are the reduction in side-effects and complications of the stimulation protocol; a clear benefit to the patients.
the
are
in
L17 ANSWER 9 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 6
AN 2000093694 EMBASE
TI No significant leukocytosis under controlled ovarian stimulation using the LHRH antagonist **Cetrorelix** and recFSH.
AU Ludwig M.; Strik D.; Felberbaum R.; Al-Hasani S.; Diedrich K.
CS M. Ludwig, Department Gynecology/Obstetrics, Medical University of Lubeck,
Ratzeburger Allee 160, 23538 Lubeck, Germany
SO European Journal of Obstetrics Gynecology and Reproductive Biology,
(2000) 89/2 (177-179).
Refs: 10
ISSN: 0301-2115 CODEN: EOGRAL
PUI S 0301-2115(99)00195-5
CY Ireland
DT Journal; Article
FS 010 Obstetrics and Gynecology
025 Hematology

003 Endocrinology
030 Pharmacology
037 Drug Literature Index

LA English
SL English

AB Objective: To study the influence of an LHRH (luteinizing hormone releasing hormone) antagonist protocol (**Cetrorelix**) and the use of recombinant follicle-stimulating hormone (FSH) on the development of leukocytosis, compared to the use of urinary **HMG** (human menopausal **gonadotrophin**). Design: Prospective, randomized phase III clinical trial. Setting: **Infertility** day clinic, Department of Gynecology and Obstetrics. Patients: Thirty patients undergoing IVF/intracytoplasmic sperm injection (ICSI) treatment following controlled ovarian stimulation using a multiple dose protocol and the LHRH antagonist **Cetrorelix**. Main outcome measure: Differences in white blood cell (WBC) count before stimulation, during the follicular phase and in the midluteal phase. Results: Statistically significant increase in WBC count in the **HMG** group from the start of stimulation to the midluteal phase. No statistically significant increase in the recFSH group, but only a trend towards higher values was observed. Conclusion: The development of a leukocytosis in controlled ovarian stimulation does not depend on the protocol used. Urinary gonadotrophins seem to have a greater potential to increase WBC count compared to recombinant gonadotrophins. Copyright (C) 2000 Elsevier Science Ireland Ltd.

L17 ANSWER 10 OF 27 BIOSIS COPYRIGHT 2001 BIOSIS
AN 2000:458002 BIOSIS
DN PREV200000458002
TI The use of GnRH antagonist for COH as a second line strategy in IVF or ICSI.
AU van Os, H. C. (1); Jansen, C. A. M. (1)
CS (1) Department of IVF, Reinier de Graaf Hospital Group, loc Diaconessenhuis Voorburg, Zaandam Netherlands
SO Human Reproduction (Oxford), (June, 2000) Vol. 15, No. Abstract Book 1, pp. 134. print.
Meeting Info.: 16th Annual Meeting of the European Society of Human Reproduction and Embryology Bologna, Italy June 25-28, 2000 European Society of Human Reproduction and Embryology
. ISSN: 0268-1161.
DT Conference
LA English
SL English

L17 ANSWER 11 OF 27 BIOSIS COPYRIGHT 2001 BIOSIS
AN 2000:457980 BIOSIS
DN PREV200000457980
TI Ovarian stimulation in poor responders using GnRH antagonists.
AU Nikolettos, N. (1); Al-Hasani, S.; Felberbaum, R.; Kupker, W.; Schopper, B.; Sturm, R.; Diedrich, K.
CS (1) Faculty of Medicine, Democritus University of Thrace, Alexandroupolis Greece
SO Human Reproduction (Oxford), (June, 2000) Vol. 15, No. Abstract Book 1, pp. 125. print.
Meeting Info.: 16th Annual Meeting of the European Society of Human Reproduction and Embryology Bologna, Italy June 25-28, 2000 European Society of Human Reproduction and Embryology
. ISSN: 0268-1161.
DT Conference
LA English
SL English

L17 ANSWER 12 OF 27 MEDLINE
AN 2001033462 MEDLINE
DN 20457105 PubMed ID: 11000511
TI Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, **cetrorelix**, and GnRH agonists.
AU Nikolettos N; Al-Hasani S; Felberbaum R; Demirel L C; Riethmuller-Winzen H; Reissmann T; Schopper B; Sturm R; Diedrich K
CS Democritus University of Thrace, Faculty of Medicine, Alexandroupolis, Greece.
SO EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY, (2000 Nov) 93 (1) 91-5.
Journal code: E4L. ISSN: 0301-2115.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200011
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001130
AB This retrospective study was performed to examine the implantation and pregnancy rates of frozen-thawed pronuclear stage oocytes obtained with the use of a GnRH antagonist, **Cetrorelix** (Cetrotide((R)) ASTA-Medica, Frankfurt/M, Germany) used in a multidose protocol with hMG, and to compare these results with those obtained after a conventional long GnRH analogue protocol (Decapeptyl-Depot, Ferring, Kiel, Germany). The study population consisted of 31 **infertile** couples with frozen-thawed pronuclear stage oocytes after ICSI treatment using the GnRH antagonist **Cetrorelix** (**Cetrorelix((R))**) and 31 **infertile** couples with frozen-thawed pronuclear stage oocytes after ICSI treatment using the long GnRH analogue protocol. Patients underwent ICSI after down regulation with a GnRH agonist (Decapeptyl) and stimulation with hMG, or a GnRH antagonist (**Cetrorelix**) and hMG. The supernumerary pronuclear stage oocytes were cryopreserved and transferred in a later mildly stimulated cycle. The implantation and pregnancy rates for frozen-thawed pronuclear stage oocytes derived from the GnRH antagonist compared with the GnRH agonist were 3.26% versus 3.73% (P=1.0000) and 8.33% versus 10.25% (P=1.0000), respectively. To our knowledge we report here the first pregnancies obtained by the transfer of cryopreserved pronuclear stage embryos generated from ICSI using a GnRH antagonist in the collecting cycle. The use of **Cetrorelix** in a multiple dose protocol in combination with hMG does not demonstrate a negative effect on viability, implantation potential or pregnancy outcome as compared to 2PN conceptuses obtained from a long GnRH agonist-hMG protocol.

L17 ANSWER 13 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 7
AN 1999201422 EMBASE
TI Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization /intracytoplasmic sperm injection cycles.
AU Albano C.; Smits J.; Tournaye H.; Riethmuller-Winzen H.; Van Steirteghem A.; Devroey P.
CS C. Albano, Center for Reproductive Medicine, University Hospital Medical School, Dutch-speaking Brussels Free Univ., Laarbeeklaan 101, 1090 Brussels, Belgium
SO Human Reproduction, (1999) 14/6 (1426-1430).
Refs: 36
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom

DT Journal; Article
FS 003 Endocrinology
010 Obstetrics and Gynecology
037 Drug Literature Index
LA English
SL English
AB The luteal phase hormonal profile and the clinical outcome of 69 patients undergoing in-vitro **fertilization** (IVF) or intracytoplasmic sperm injection (ICSI) after ovarian stimulation with human menopausal **gonadotrophin** (HMG) and the **gonadotrophin**-releasing hormone (GnRH) antagonist **Cetrorelix** were analysed. Twenty-four patients received **Cetrorelix** 0.5 mg (group I) while in 45 patients **Cetrorelix** 0.25 mg was administered (group II). Human chorionic **gonadotrophin** (HCG) was used as luteal support. Nine clinical pregnancies were obtained in group I (37.5%) and 12 in group II (26.6%). These results were not significantly different. Serum progesterone and oestradiol concentrations did not differ between the two groups either in pregnant or non-pregnant patients. An expected decrease of the same hormones was observed 8 days after the preovulatory HCG injection in non-pregnant women. With regard to serum luteinizing hormone concentrations, a decrease was observed 2 days after the pre-ovulatory HCG injection and was maintained at almost undetectable levels throughout the entire luteal phase in both conception and non-conception cycles of group I and group II. This study demonstrates that different doses of GnRH antagonist do not have any impact on the luteal phase of IVF/ICSI cycles when hormonal support is given.

L17 ANSWER 14 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 8
AN 1999133653 EMBASE
TI Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro **fertilization** either with **gonadotrophin**-releasing hormone agonist or **gonadotrophin**-releasing hormone antagonist?
AU Lin Y.; Kahn J.A.; Hillensjo T.
CS J.A. Kahn, Department Obstetrics Gynaecology, University Hospital of Trondheim, N-7006 Trondheim, Norway
SO Human Reproduction, (1999) 14/4 (885-888).
Refs: 21
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 002 Physiology
021 Developmental Biology and Teratology
037 Drug Literature Index
LA English
SL English
AB **Gonadotrophin**-releasing hormone (GnRH) regulates **gonadotrophin** release. It has been shown that GnRH may have a direct effect on the ovary, as the addition of GnRH to granulosa cell cultures inhibits the production of progesterone and oestradiol. Specific GnRH receptors have been found to be present in rat and human granulosa cells. Desensitization of the pituitary by GnRH agonist has become common in in-vitro **fertilization** (IVF) treatment, usually by a long protocol of 2-3 weeks. With the introduction of GnRH antagonists, which produce an immediate blockage of the GnRH receptors, a much shorter exposure is needed of 3-6 days. The aim of this study was to evaluate the effect of a GnRH agonist (buserelin) and a GnRH antagonist (**cetrorelix**) on the function of granulosa cells cultured in vitro from IVF patients. Women were treated by IVF randomized either to have buserelin nasal spray from the luteal phase in the previous cycle or **cetrorelix** from day 6 of the cycle. Both groups had ovarian stimulation with human menopausal **gonadotrophin** (HMG) 150 IU daily, i.e. HCG was administered when the follicles were larger

than 17 mm, and aspirated 36 h later. Granulosa cells, separated and washed from large follicles containing ova, were pooled. After 48 h of pre-incubation, the granulosa cells were cultured for 4 days in medium with either added testosterone or cAMP with or without HCG, with change

of
the
medium after 2 days. The progesterone and oestradiol concentrations in

the culture medium were measured by immunological assay, and cellular protein was measured by microprotein assay. The results showed that granulosa cells from women treated with GnRH antagonist (**cetrorelix**) responded earlier to the in-vitro hormone stimulation in terms of progesterone accumulation than women treated with the GnRH agonist (buserelin). This may have been due to difference in time of exposure to the analogue. The results may indicate that the luteal function is less impaired in GnRH antagonist treatment than in GnRH agonist treatment.

L17 ANSWER 15 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 9
AN 1999100542 EMBASE
TI Revival of the natural cycles in in-vitro **fertilization** with the use of a new **gonadotrophin**-releasing hormone antagonist (**Cetrorelix**): A pilot study with minimal stimulation.
AU Rongieres-Bertrand C.; Olivennes F.; Righini C.; Fanchin R.; Taieb J.; Hamamah S.; Bouchard P.; Frydeman R.
CS F. Olivennes, Department Obstetrics and Gynecology, A. Beclere Hospital, 157 Rue de la Porte de Trivaux, 92140 Clamart Cedex, France
SO Human Reproduction, (1999) 14/3 (683-688).
Refs: 54
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 010 Obstetrics and Gynecology
030 Pharmacology
037 Drug Literature Index
LA English
SL English

AB Natural cycles were abandoned in in-vitro **fertilization** (IVF) embryo transfer, due to premature luteinizing hormone (LH) surges - and subsequent high cancellation rates. In this study, we investigated the administration of a new **gonadotrophin**-releasing hormone antagonist (**Cetrorelix**) in the late follicular phase of natural cycles in patients undergoing IVF and intracytoplasmic sperm injection (ICSI). A total of 44 cycles from 33 healthy women [mean age 34.1 .+-.

1.4 (range 26-36) years] were monitored, starting on day 8 by daily ultrasound and measurement of serum concentrations of oestradiol, LH, follicle stimulating hormone (FSH) and progesterone. When plasma oestradiol concentrations reached 100-150 pg/ml, with a lead follicle between 12-14 mm diameter, a single injection (s.c.) of 0.5 mg (19 cycles) or 1 mg (25 cycles) **Cetrorelix** was administered. Human menopausal **gonadotrophin** (HMG; 150 IU) was administered daily at the time of the first injection of **Cetrorelix**, and repeated thereafter until human chorionic **gonadotrophin** (HCG) administration. Four out of 44 cycles were cancelled (9.0%). No decline in

follicular growth or oestradiol secretion was observed after **Cetrorelix** administration. A total of 40 oocyte retrievals leading to 22 transfers (55%) was performed. In 10 cycles (25%), no oocyte was obtained. **Fertilization** failure despite ICSI occurred in six cycles (15%). In two patients the embryo was arrested at the 2 pronuclear (PN) stage. The stimulation was minimal (4.7 .+-. 1.4 HMG ampoules). A total of seven clinical pregnancies was obtained (32.0% per transfer, 17.5% per retrieval), of which five are ongoing. Thus, a spontaneous cycle and the GnRH antagonist **Cetrorelix** in single dose administration could represent a first-choice IVF treatment with

none

of the complications and risks of current controlled ovarian hyperstimulation protocols, and an acceptable success rate.

L17 ANSWER 16 OF 27 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1999:392736 BIOSIS
DN PREV199900392736
TI A prospective randomized study comparing the use of hMG versus rec-FSH with the single dose GnRH antagonist (**Cetrorelix**) protocol in IVF-embryo transfer.
AU Olivennes, F. (1); Belaich-Allart, J.; Alvarez, S.; Bouchard, P.; Frydman,
R. (1)
CS (1) Obstetric and Gynecologic Department, Hospital A. Beclere, Clamart
France
SO Human Reproduction (Oxford), (June, 1999) Vol. 14, No. ABSTR. BOOK 1, pp.
61.
Meeting Info.: 15th Annual Meeting of the European Society of Human
Reproduction and Embryology and the Annual Meeting of the Federation
Francaise pour l'Etude de la Reproduction Tours, France June 26-30, 1999
European Society of Human Reproduction and Embryology
. ISSN: 0268-1161.
DT Conference
LA English

L17 ANSWER 17 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 10
AN 1998262426 EMBASE
TI The luteal phase of nonsupplemented cycles after ovarian superovulation
with human menopausal gonadotropin and the gonadotropin-releasing hormone
antagonist **Cetrorelix**.
AU Albano C.; Grimbizis G.; Smitz J.; Riethmuller-Winzen H.; Reissmann T.;
Van Steirteghem A.; Devroey P.
CS Dr. C. Albano, Centre for Reproductive Medicine, Brussels Free
University,
Laarbeeklaan 101, 1090 Brussels, Belgium. LRIAOC@AZ.VUB.AC.BE
SO Fertility and Sterility, (1998) 70/2 (357-359).
Refs: 4
ISSN: 0015-0282 CODEN: FESTAS
PUI S 0015-0282(98)00135-6
CY United States
DT Journal; Article
FS 010 Obstetrics and Gynecology
037 Drug Literature Index
LA English
SL English
AB Objective: To analyze the luteal phase of six patients undergoing
controlled ovarian hyperstimulation (COH) with hMG and a new
GnRH antagonist, **Cetrorelix**, without receiving luteal phase
supplementation. Design: Phase II study involving the first six patients
who did not receive luteal phase support. Setting: Tertiary referral
center. Patient(s): Six healthy women undergoing COH for assisted
reproductive techniques. Intervention(s): Oocyte retrieval was performed
36 hours after hCG administration, followed by embryo transfer 2 days
later. No luteal phase supplementation was given. Main Outcome
Measure(s):
Serum E2, progesterone, LH, and FSH concentrations were measured.
Result(s): The length of the luteal phase was .1 to <12 days in three of
the six patients. One of the patients in whom the luteal phase was >12
days had a low serum progesterone concentration (2.9 ng/mL) on day 10.
Serum LH concentrations decreased after the preovulatory hCG injection in
all patients. However, a progressive increase in LH was observed after
day 7, reaching normal values. Conclusion(s): Corpus luteum function seems to
be impaired in cycles that are stimulated with hMG and the GnRH
antagonist **Cetrorelix**.

L17 ANSWER 18 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 1998311417 EMBASE
TI New approaches to ovarian stimulation.
AU Diedrich K.; Felberbaum R.; Jones H.; Brinsden P.; Edwards R.G.; Howles C.; Cohen J.; Fanchin R.; Oehninger S.
CS K. Diedrich, Department Obstetrics Gynecology, Medical University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
SO Human Reproduction, (1998) 13/SUPPL. 3 (1-17).
Refs: 44
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Conference Article
FS 010 Obstetrics and Gynecology
037 Drug Literature Index
LA English
SL English
AB Suppression of endogenous hormone production by gonadotrophin-releasing hormone (GnRH) agonists followed by controlled ovarian hyperstimulation (COH) with human gonadotrophins, especially the so-called 'long protocol' has developed from second-line into first-line therapy. Due to this attitude premature luteinization can be safely avoided, enhancing therapeutic efficacy. Recombinant preparations of human follicle stimulating hormone (FSH) have been proven to be effective within COH according to the long protocol. The high purity of these compounds may have clinical advantages. GnRH antagonists could be successfully introduced in COH protocols. Also, daily injections in the midcycle phase according to the 'Lubeck protocol', as single or only dual administrations around day 9 seem to abolish any premature LH rises. Due to their different pharmacological mode of action, based on a classic competitive receptor blockage GnRH antagonists avoid any flare-up period and allow ovarian stimulation to start within the spontaneous cycle. Pregnancy rates are comparable to those after long protocol stimulation. Combination of softer stimulation regimes like clomiphene citrate and low dose HMG with midcycle administration of GnRH antagonists may be the way to a cheap, safe and efficient ovarian stimulation. It seems to be high time for modest forms of ovarian stimulation, lowering burden and risk for our patients.

L17 ANSWER 19 OF 27 MEDLINE
AN 97277516 MEDLINE
DN 97277516 PubMed ID: 9130900
TI Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
AU Albano C; Smitz J; Camus M; Riethmuller-Winzen H; Van Steirteghem A; Devroey P
CS Centre for Reproductive Medicine, Dutch-speaking Brussels Free University, Belgium.
SO FERTILITY AND STERILITY, (1997 May) 67 (5) 917-22.
Journal code: EVF; 0372772. ISSN: 0015-0282.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199705
ED Entered STN: 19970523
Last Updated on STN: 19970523
Entered Medline: 19970515
AB OBJECTIVE: To assess the minimal effective dose of a GnRH antagonist (Cetrorelix; Asta Medical; Frankfurt, Germany) to prevent premature

LH surge in patients undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies. DESIGN: In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (**Cetrorelix**) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection. In 32 and 30 patients, 0.5 mg and 0.25 mg of **Cetrorelix** were administered, respectively. Seven patients received 0.1 mg of **Cetrorelix**. SETTING: Tertiary referral center. RESULT(S): No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of **Cetrorelix**, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups. Follicle-stimulating hormone, LH, E2, and P expressed as area under the curve were similar in both groups. A premature LH surge (18 mIU/mL; conversion factor to SI unit, 1.00) with a concomitant P rise (1.7 micrograms/L; conversion factor to SI unit, 3.180) occurred in one of the seven patients treated with 0.1 mg **Cetrorelix**; therefore, treatment with this dose was discontinued. CONCLUSION(S): The minimal effective dose of **Cetrorelix** able to prevent premature LH surge in COH cycles is 0.25 mg administered daily.

L17 ANSWER 20 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 11
AN 96357183 EMBASE
DN 1996357183
TI Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal **gonadotrophin** and **gonadotrophin**-releasing hormone antagonist (**Cetrorelix**).
AU Albano C.; Smitz J.; Camus M.; Riethmuller-Winzen H.; Siebert-Weigel M.; Diedrich K.; Van Steirteghem A.C.; Devroey P.
CS Centre for Reproductive Medicine, University Hospital Medical School, Dutch-speaking Brussels Free Univ., Laarbeeklaan 101, 1090 Brussels, Belgium
SO Human Reproduction, (1996) 11/10 (2114-2118).
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 010 Obstetrics and Gynecology
037 Drug Literature Index
LA English
SL English
AB A third-generation **gonadotrophin**-releasing hormone antagonist (**Cetrorelix**) was used during ovarian stimulation in 32 patients undergoing assisted reproduction, in order to prevent the premature luteinizing hormone (LH) surge. In all patients, ovarian stimulation was carried out with two or three ampoules of human menopausal **gonadotrophin** (hMG), starting on day 2 of the menstrual cycle. In addition, 0.5 mg of **Cetrorelix** was administered daily from day 6 of hMG treatment until the day of ovulation induction by human chorionic **gonadotrophin** (hCG). A significant drop in plasma LH concentration was observed within a few hours of the first administration of **Cetrorelix** ($P < 0.005$). Moreover, no LH surge was detected at any point in the treatment period in any of the 32 patients. A mean oestradiol concentration of 2122 .+- . 935 ng/l was observed on the day of the hCG administration, indicating normal folliculogenesis. Like LH, progesterone concentration also dropped within a few hours of the first administration of **Cetrorelix** ($P < 0.005$). A 0.5 mg daily dose of **Cetrorelix** prevented a premature LH surge in all the 32 patients treated.

L17 ANSWER 21 OF 27 MEDLINE
AN 96324678 MEDLINE
DN 96324678 PubMed ID: 8671476

TI Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist **cetrorelix** in intracytoplasmic sperm injection cycles.

AU Ubaldi F; Albano C; Peukert M; Riethmuller-Winzen H; Camus M; Smitz J;

Van Steirteghem A; Devroey P

CS Centre for Reproductive Medicine, Dutch-speaking Brussels Free University, Brussels, Belgium.

SO HUMAN REPRODUCTION, (1996 Jul) 11 (7) 1405-7.
Journal code: HRP; 8701199. ISSN: 0268-1161.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199611

ED Entered STN: 19961219
Last Updated on STN: 19961219
Entered Medline: 19961106

AB In the present study, subtle serum progesterone rise (≥ 1.1 ng/ml) during the late follicular phase is reported, for the first time to our knowledge, in patients using a potent gonadotrophin-releasing hormone (GnRH) antagonist, **Cetrorelix**, in combination with human menopausal gonadotrophin (hMG) for ovarian stimulation prior to intracytoplasmic sperm injection (ICSI). In five out of 24 patients (20%) serum progesterone levels were ≥ 1.1 ng/ml. The cycle characteristics of the patients were similar in both groups. No premature endogenous luteinizing hormone (LH) surge occurred and the serum LH concentrations were constantly low during the follicular phase. The 17-beta oestradiol and follicle stimulating hormone (FSH) exposure were higher in cycles with premature luteinization. The greater oestradiol and FSH exposure confirm that one of the possible factors inducing subtle serum progesterone rise is the increased oestradiol and FSH-induced LH receptivity in granulosa cells.

L17 ANSWER 22 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 12

AN 96083720 EMBASE

DN 1996083720

TI Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist **Cetrorelix** at different dosages.

AU Felberbaum R.; Reissmann T.; Kupker W.; Al-Hasani S.; Bauer O.; Schill T.; Zoll C.; Diedrich C.; Diedrich K.

CS Department of Obstetrics/Gynecology, Medical University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany

SO Journal of Assisted Reproduction and Genetics, (1996) 13/3 (216-222).
ISSN: 1058-0468 CODEN: JARGE4

CY United States

DT Journal; Article

FS 010 Obstetrics and Gynecology
037 Drug Literature Index
038 Adverse Reactions Titles

LA English

SL English

AB Purpose: The premature LH surge in ART programs seems to be avoided by daily administration of the GnRH-antagonist **Cetrorelix** during the midcycle phase in controlled ovarian hyperstimulation with hMG. The dosage necessary for sufficient suppression of the pituitary gland is not yet defined. Methods: To elucidate this question three daily dosages (3, 1, 0.5 mg) were administered and the hormone profiles obtained as well as the number of oocytes retrieved, the fertilization

rate, and the consumption of hMG were compared. Results: No premature LH surge could be observed at any of the three dosages administered. Both gonadotropins were deeply suppressed. The fertilization rates of the oocytes obtained were 45.3% in the 3-mg group, 53.1% in the 1-mg group, and 67.7% in the 0.5-mg group. The average

uses of hMG ampoules were 30 in the 3-mg group, 27 in the 1-mg group, and 26 in the 0.5-mg group. Conclusions: Cetrolrix, 0.5 mg/day, administered during the midcycle phase of controlled ovarian hyperstimulation with hMG is enough to prevent completely the premature LH surge. Perhaps even lower dosages would be sufficient. Regarding fertilization rates and use of hMG, the lower dosage seems to be the most favorable.

L17 ANSWER 23 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 13
AN 95280014 EMBASE
DN 1995280014
TI Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview.
AU Reissmann Th.; Felberbaum R.; Diedrich K.; Engel J.; Comaru-Schally A.M.; Schally A.V.
CS ASTA Medica AG, Frankfurt-M, Germany
SO Human Reproduction, (1995) 10/8 (1974-1981).
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
010 Obstetrics and Gynecology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB Luteinizing hormone-releasing hormone (LHRH) plays a crucial role in controlling the ovarian cycle in women. By modification of the molecular structure of this decapeptide, analogues were synthesized with agonistic or antagonistic effects on the gonadotrophic cells of the anterior pituitary gland. The agonists, after an initial stimulatory effect ('flare up'), lead to desensitization of the gonadotrophic cells and a reduction in the number of LHRH receptors on the cell membrane ('down-regulation'), while the antagonists produce an immediate effect by competitive blockade of the LHRH receptors. After administration of LHRH antagonists, the serum levels of FSH and LH decrease within hours. Nevertheless, the adenohypophysis maintains its responsiveness to an LHRH stimulus ('pituitary response') after pretreatment with an antagonist. This different pharmacological mechanism of LHRH antagonists makes possible new approaches to ovarian stimulation and to the therapy of sex steroid dependent diseases. The premature LH surge, the main cause of cancellation during induction of superovulation in assisted reproduction technology (ART) programmes, can be abolished by short term application of an LHRH antagonist associated with a reduced human menopausal gonadotrophin (hMG) requirement for ovarian stimulation. A future approach to ART might be based on the combination of pretreatment with an LHRH antagonist and ovulation induction by native LHRH or an agonist. The severe side effects encountered with early LHRH antagonists, such as anaphylactoid reactions due to histamine release, are almost completely eliminated in modern antagonists, especially Cetrorelix which is presently used clinically in controlled phase II clinical studies.

AN 95213899 EMBASE
DN 1995213899
TI Preserved pituitary response under ovarian stimulation with hMG and GnRH antagonists (**Cetrorelix**) in women with tubal infertility.
AU Felberbaum R.E.; Reissmann T.; Kupke W.; Bauer O.; Al Hasani S.; Diedrich C.; Diedrich K.
CS Department of Obstetrics/Gynecology, Medical University of Lubeck, Lubeck, Germany
SO European Journal of Obstetrics Gynecology and Reproductive Biology, (1995) 61/2 (151-155).
ISSN: 0028-2243 CODEN: EOGRAL
CY Ireland
DT Journal; Article
FS 010 Obstetrics and Gynecology
 037 Drug Literature Index
LA English
SL English
AB Objective: To examine the pituitary response in patients undergoing short-term application of the GnRH antagonist **Cetrorelix** in the mid-cycle phase for hypophysial suppression of premature LH surges within an IVF-program. Design: Twenty patients suffering from primary or secondary tubal infertility were stimulated with hMG from cycle day 2. From day 7 till ovulation induction **Cetrorelix** was administered in two different dose regimens (15 patients 3 mg s.c. daily; 5 patients 1 mg s.c. daily). Three hours before ovulation induction a GnRH test was performed using 25 .mu.g of native GnRH and the pituitary response examined by measurement of the serum LH concentration after 30 min. Results: Premature LH surges could be avoided in the 3-mg group and in the 1-mg group, respectively. Due to this, none of the cycles had to be cancelled. Oestradiol profiles and ultrasound demonstrated a satisfactory follicular maturation. All patients showed pronounced suppression of the serum LH levels before ovulation induction. The mean increase of serum LH due to the performed GnRH test was 10 mIU/ml for the 3-mg group, while the average maximum in the 1-mg group was about 32.5 mIU/ml. Conclusions: The pituitary response is preserved by the treatment with the GnRH antagonist **Cetrorelix**. The extent of suppression of the adenohypophysis, as expressed by the different reactions on GnRH test, can be modulated by the dosage administered. This should allow ovulation induction by GnRH or one of its agonists instead of hCG, which could be beneficial in patients at high risk of Ovarian Hyperstimulation Syndrome (OHSS) and those suffering from Polycystic Ovary Disease (PCOD).
L17 ANSWER 25 OF 27 MEDLINE
AN 96213256 MEDLINE
DN 96213256 PubMed ID: 8672908
TI [GnRH antagonists in gynecology: initial results within the scope of controlled ovarian hyperstimulation]. Die GnRH-Antagonisten in der Gynakologie: Erste Ergebnisse im Rahmen der kontrollierten ovariellen Hyperstimulation (COH).
AU Felberbaum R; Reissmann T; Zoll C; Kupker W; al-Hasani S; Diedrich C; Diedrich K
CS Klinik fur Frauenheilkunde und Geburtshilfe der Medizinischen Universitat zu Lubeck.
SO GYNAKOLOGISCH-GEBURTSHILFLICHE RUNDSCHAU, (1995) 35 Suppl 1 113-7.
Journal code: BK6; 9212667. ISSN: 1018-8843.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals

EM 199608
ED Entered STN: 19960822
Last Updated on STN: 19960822
Entered Medline: 19960812
AB OBJECTIVE: Applicability of the GnRH-antagonist **Cetrorelix** within controlled ovarian hyperstimulation (COH) to avoid the premature LH-surge should be examined. METHODS: 35 patients suffering from tubal **infertility** were stimulated for In Vitro **Fertilization** (IVF) by human menopausal gonadotrophins (HMG) and concomitant administration of **Cetrorelix** in different dosages (3 mg, 1 mg, 0,5 mg). RESULTS: No premature LH-surge could be observed. CONCLUSIONS: Short term administration of the GnGR-antagonists avoids the occurrence of a premature LH-surge.
of

L17 ANSWER 26 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 15
AN 94179324 EMBASE
DN 1994179324
TI Suppression of the endogenous luteinizing hormone surge by the **gonadotrophin**-releasing hormone antagonist **Cetrorelix** during ovarian stimulation.
AU Diedrich K.; Diedrich C.; Santos E.; Zoll C.; Al-Hasani S.; Reissmann T.; Krebs D.; Klingmuller D.
CS Clinic Gynaecology and Obstetrics, University of Lubeck, Lubeck, Germany
SO Human Reproduction, (1994) 9/5 (788-791).
ISSN: 0268-1161 CODEN: HUREEE
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
010 Obstetrics and Gynecology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
AB Surges of luteinizing hormone (LH) that result in luteinization but occur prematurely with respect to the diameter of the leading follicle, prevent attempts to induce multiple follicular maturation for in-vitro **fertilization** (IVF) in a significant number of women. We examined the possibility of blocking premature LH surges by the administration of **Cetrorelix** a potent antagonist of **gonadotrophin**-releasing hormone (GnRH), in a study including 20 patients, some of whom had previously shown premature LH surges. All patients were treated with human menopausal gonadotrophins (HMG) starting on day 2. From day 7 until the induction of ovulation by human chorionic **gonadotrophin** (HCG) the GnRH antagonist **Cetrorelix** was given daily. HCG was injected when the dominant follicle had reached a diameter of >18 mm and oestradiol concentration was >300 pg/ml for each follicle having a diameter of >15 mm. Oocyte collection was performed 36 h later by transvaginal ultrasound puncture, followed by IVF and embryo transfer. The hormone profiles of these patients and the results of IVF and embryo transfer are comparable to those treated with GnRH agonists and HMG. However, less time and especially less HMG is needed in comparison to patients stimulated with a long agonist protocol. Hence, treatment with **Cetrorelix** proved to be much more comfortable for the patient. In this study we showed that combined treatment with gonadotrophins and the GnRH antagonist **Cetrorelix** is a promising method for ovarian stimulation in patients who frequently exhibit premature LH surges and therefore fail to complete treatment.

L17 ANSWER 27 OF 27 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 16
AN 94277948 EMBASE
DN 1994277948

TI The single or dual administration of the gonadotropin-releasing hormone antagonist **Cetrorelix** in an in vitro **fertilization**-embryo transfer program.
AU Olivennes F.; Fanchir R.; Bouchard P.; De Ziegler D.; Taieb J.; Selva J.; Frydman R.
CS Dept. of Obstetrics and Gynecology, Antoine Beclere Hospital, 157, rue de la porte de trivaux, 92141 Clamart Cedex, France
SO Fertility and Sterility, (1994) 62/3 (468-476).
ISSN: 0015-0282 CODEN: FESTAS
CY United States
DT Journal; Article
FS 010 Obstetrics and Gynecology
 037 Drug Literature Index
LA English
SL English
AB Objective: To assess the ability of a GnRH antagonist (**Cetrorelix**, Asta Medica AG, Frankfurt, Germany) to prevent premature LH surges in an IVF-ET program using a simple protocol with one or two administrations. Design: Controlled ovarian hyperstimulation was carried out in 17 women with three ampules a day of hMG, starting on day 2 of the menstrual cycle. A dose of 5 mg of **Cetrorelix** was administered when plasma E2 levels were between 150 and 200 pg/mL (conversion factor to S1 unit, 3.671) per follicle of .gtoreq. 14 mm. A second injection was performed 48 hours later if the triggering of ovulation was not decided in the meantime. Results: Six patients received one injection and 11 patients received two administrations. Plasma LH levels showed a marked decrease and remained low after the administration of the GnRH antagonist. In six patients, the first administration of **Cetrorelix** was performed when a significant rise in LH plasma level was present. Even in these patients the GnRH antagonist was able to prevent an LH surge. The tolerance of the product was good. Six clinical pregnancies were obtained, of which four are ongoing (25% per ET). Two ongoing pregnancies were obtained after the transfer of a frozen-thawed embryo (35.3% per retrieval). Conclusions: The GnRH antagonist **Cetrorelix** in a simple, unique or dual administration, protocol was able to prevent premature LH surge in all of the 17 patients studied. If these results are confirmed by larger, randomized studies, the good tolerance and efficacy that we observed suggest a bright future for this product in assisted reproductive technologies.

=> d his

(FILE 'HOME' ENTERED AT 12:32:54 ON 17 JUL 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA, LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:33:40 ON 17 JUL 2001
E ENGEL JURGEN/AU
L1 209 S E3-E4
 E WICHERT BURKHARD/AU
L2 12 S E3-E4
 E SAUERBIAR DEITER/AU
 E SAUERBIER DEITER/AU
L3 42 S E2-E5
 E REISSMANN THOMAS/AU
L4 54 S E1-E4
L5 284 S L1-L4

L6 52 S L5 AND CETRORELIX
L7 38 DUP REM L6 (14 DUPLICATES REMOVED)
L8 11 S L7 AND (INFERTIL? OR FERTILI?)
L9 17 S L6 AND (INFERTIL? OR FERTILI?)
L10 14 DUP REM L9 (3 DUPLICATES REMOVED)
L11 1 S L10 AND GONADOTROPHIN?
L12 687340 S INFERTIL? OR FERTIL?
L13 229 S L12 AND CETRORELIX
L14 141 S L13 AND (FEMALE OR GONADOTRPOHIN)
L15 165 S L13 AND (FEMALE OR GONADOTROPHIN)
L16 61 S L15 AND HMG
L17 27 DUP REM L16 (34 DUPLICATES REMOVED)

=> s l13 and (hexitol or mannitol or glucitol or sorbitol or dulcitol or allitol or iditol or urea or sodium chloride)

7 FILES SEARCHED...
L18 8 L13 AND (HEXITOL OR MANNITOL OR GLUCITOL OR SORBITOL OR DULCITO L OR ALLITOL OR IDITOL OR UREA OR SODIUM CHLORIDE)

=> s l18 and bulking agent

L19 0 L18 AND BULKING AGENT

=> dup rem l18

PROCESSING COMPLETED FOR L18
L20 7 DUP REM L18 (1 DUPLICATE REMOVED)

=> d bib ab 1-7

L20 ANSWER 1 OF 7 USPATFULL DUPLICATE 1
AN 2001:14464 USPATFULL
TI Pharmaceutical formulations for sustained drug delivery
IN Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 6180608 B1 20010130
AI US 1997-988851 19971211 (8)
RLI Continuation-in-part of Ser. No. US 1996-762747, filed on 11 Dec 1996,
now patented, Pat. No. US 5968895
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner:
Delacroix-Muirheid, C.
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained delivery formulations comprising a water-insoluble complex of
a peptidic compound (e.g., a peptide, polypeptide, protein,
peptidomimetic or the like) and a carrier macromolecule are disclosed.
The formulations of the invention allow for loading of high
concentrations of peptidic compound in a small volume and for delivery
of a pharmaceutically active peptidic compound for prolonged periods,
e.g., one month, after administration of the complex. The complexes of
the invention can be milled or crushed to a fine powder. In powdered
form, the complexes form stable aqueous suspensions and dispersions,
suitable for injection. In a preferred embodiment, the peptidic
compound

of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L20 ANSWER 2 OF 7 USPATFULL
AN 2001:52022 USPATFULL
TI GnRH antagonists being modified in positions 5 and 6
IN Semple, Graeme, Gothenburg, Sweden
Jiang, Guangcheng, San Diego, CA, United States
PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)
PI US 6214798 B1 20010410
WO 9846634 19981022
AI US 2000-402698 20000103 (9)
WO 1998-US7438 19980413
20000103 PCT 371 date
20000103 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1997-837042, filed on 11 Apr 1997,
now patented, Pat. No. US 5925730
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner:
Delacroix-Muirheid, C.
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate **fertility** and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- or the 5- and 6-positions. This derivative is modified so as to contain a carbamoyl group or heterocycle, including a **urea** moiety, in its side chain.
Decapeptides having the formula:

Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-hydroorotyl)-D-4Amf(Q.sub.2)-Leu-Lys(isopropyl)-Pro-Xaa.sub.10,

wherein Q.sub.2 is Cbm or MeCbm and Xaa.sub.10 is D-Ala-ol or Ala-ol
are particularly effective and continue to exhibit very substantial suppression of LH secretion at 96 hours following injection.

L20 ANSWER 3 OF 7 USPATFULL
AN 1999:128511 USPATFULL
TI Pharmaceutical formulations for sustained drug delivery
IN Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5968895 19991019
AI US 1996-762747 19961211 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner:
Delacroix-Muirheid, C.
LREP Lahive & Cockfield, LLP, Mandragouras, Amy E., DeConti, Giulio A.
CLMN Number of Claims: 32
ECL Exemplary Claim: 10

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 775

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex.

The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L20 ANSWER 4 OF 7 USPATFULL

AN 1999:81921 USPATFULL

TI GnRH antagonists

IN Semple, Graeme, Hampshire, United Kingdom

Jiang, Guangcheng, San Diego, CA, United States

PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)

PI US 5925730 19990720

AI US 1997-837042 19970411 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Hill, Jr., Robert J.; Assistant Examiner:
Delacroix-Muirheid, C.

LREP Fitch, Even, Tabin & Flannery

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1458

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate **fertility** and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- and/or 6-positions. This derivative

contains a carbamoyl group or a heterocycle including a **urea** in its side chain. Particularly effective decapeptides, which continue to exhibit very substantial suppression of LH secretion at 96 hours following injection, have the formulae: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, and Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Amf(Q.sub.2)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, wherein Q.sub.2 is Cbm or MeCbm.

L20 ANSWER 5 OF 7 USPATFULL

AN 1998:124554 USPATFULL

TI GnRH antagonist decapeptides

IN Jiang, Guangcheng, San Diego, CA, United States

Semple, Graeme, Hampshire, United Kingdom

PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)

PI US 5821230 19981013

AI US 1997-837041 19970411 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Wang, Cecilia F.

LREP Fitch, Even, Tabin & Flannery

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1630

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides are provided which have improved duration of GnRH antagonistic properties and/or which can be synthesized more economically. These antagonists may be used in the same manner as the compounds of which they are analogs to regulate **fertility** and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. One particularly effective peptide, a decapeptide

analog of the GnRH antagonist Acyline, has the formula:

Ac-D-2Nal-D-4Cpa-D-Dpr(methylcarbamoyl)-Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2. It continues to exhibit very substantial suppression of LH secretion at 96 hours following injection.

Other economically attractive and pharmacologically effective analogs have the formulas: Ac-D-2Nal-D-4Cpa-Xaa.sub.3 -Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2 ; and Ac-D-2Nal-D-4Cpa-Xaa.sub.3 -Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, wherein Xaa.sub.3 is D-Gln or Gln.

L20 ANSWER 6 OF 7 USPATFULL

AN 97:78416 USPATFULL

TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases

IN Engel, Juergen, Alzenau, Germany, Federal Republic of Hilgard, Peter, Frankfurt, Germany, Federal Republic of

Reissmann, Thomas, Frankfurt, Germany, Federal Republic of

PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

PI US 5663145 19970902

AI US 1994-354838 19941208 (8)

PRAI DE 1993-4342091 19931209

DT Utility

FS Granted

EXNAM Primary Examiner: Russel, Jeffrey E.

LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 7

DRWN No Drawings

LN.CNT 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L20 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2001 ACS

AN 1994:587330 CAPLUS

DN 121:187330

TI Preparation of a **cetrorelix** lyophilized composition

IN Engel, Juergen; Sauerbier, Dieter; Wichert, Burkhard; Reissmann, Thomas

PA Asta Medica AG, Germany

SO Eur. Pat. Appl., 5 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

| | | | | | |
|------|---|----|----------|-----------------|----------|
| PI | EP 611572 | A2 | 19940824 | EP 1994-101672 | 19940204 |
| | EP 611572 | A3 | 19950111 | | |
| | EP 611572 | B1 | 20000607 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, | | | | |
| SE | DE 4305225 | A1 | 19940825 | DE 1993-4305225 | 19930219 |
| | EP 947200 | A2 | 19991006 | EP 1999-102340 | 19940204 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |
| IE | AT 193653 | E | 20000615 | AT 1994-101672 | 19940204 |
| | ES 2148247 | T3 | 20001016 | ES 1994-101672 | 19940204 |
| | CZ 284314 | B6 | 19981014 | CZ 1994-312 | 19940214 |
| | CZ 285768 | B6 | 19991117 | CZ 1998-974 | 19940214 |
| | AU 9455235 | A1 | 19940825 | AU 1994-55235 | 19940217 |
| | AU 671881 | B2 | 19960912 | | |
| | JP 06271476 | A2 | 19940927 | JP 1994-20532 | 19940217 |
| | PL 177177 | B1 | 19991029 | PL 1994-302266 | 19940217 |
| | CA 2115943 | AA | 19940820 | CA 1994-2115943 | 19940218 |
| | FI 9400779 | A | 19940820 | FI 1994-779 | 19940218 |
| | NO 9400564 | A | 19940822 | NO 1994-564 | 19940218 |
| | ZA 9401136 | A | 19940829 | ZA 1994-1136 | 19940218 |
| | BR 9400617 | A | 19940927 | BR 1994-617 | 19940218 |
| | HU 67117 | A2 | 19950228 | HU 1994-481 | 19940218 |
| | HU 218281 | B | 20000728 | | |
| | CN 1112019 | A | 19951122 | CN 1994-101378 | 19940218 |
| | RU 2145234 | C1 | 20000210 | RU 1994-5001 | 19940218 |
| PRAI | DE 1993-4305225 | A | 19930219 | | |
| | EP 1994-101672 | A3 | 19940204 | | |
| AB | A lyophilizate of a peptide with 3-15 amino acid residues (e.g. cetrorelix) and .gtoreq.1 optional matrix materials (e.g. mannitol) is prep'd. by dissolving in 100-10,000 wt. parts AcOH, dilg. with water, and lyophilizing the resulting soln. The lyophilizate is useful for prepn. of a medication for treatment of female infertility and protection of the gonads from the follicular hyperstimulation seen with other infertility treatments. | | | | |

=> d clm 1 2

| | | |
|-----|--|--------------|
| L20 | ANSWER 1 OF 7 USPATFULL | DUPPLICATE 1 |
| CLM | What is claimed is: | |
| | 1. A packaged formulation for treating a subject for a condition treatable with an LHRH analogue, comprising: a solid ionic complex of an LHRH angalogue and a carrier macromolecule packaged with instructions for fusing the complex for treating a subject having a condition treatable with an LHRH analogue, wherein the peptide content of said complex is 57% to 80% by weight. | |
| an | | |
| the | | |
| | 2. The packaged formulation of claim 1, wherein the LHRH analogue has the following structure: Ac-D-Nal.sup.1, 4-Cl-D-Phe.sup.2, D-Pal.sup.3, N-Me-Tyr.sup.5, D-Asn.sup.6, Lys(iPr).sup.8, D-Ala.sup.10 -LHRH, and the carrier macromolecule is carboxymethylcellulose, or a pharmaceutically acceptable salt thereof. | |
| | | |
| | 3. In a syringe having a lumen, the improvement comprises, inclusion of a liquid suspension of a solid ionic complex of an LHRH analogue and a carrier macromolecule in the lumen, wherein the peptide content of said complex is 57% to 80% by weight. | |
| | | |
| | 4. The syringe of claim 3, wherein the LHRH analogue has the following structure: Ac-D-Nal.sup.1, 4-Cl-D-Phe.sup.2, D-Pal.sup.3, | |

the

N-Me-Tyr.sup.5, D-Asn.sup.6, Lys(iPr).sup.8, D-Ala.sup.10 -LHRH, and carrier macromolecule is carboxymethylcellulose, or a pharmaceutically acceptable salt thereof.

5. A method for treating a subject for a condition treatable with an LHRH analogue, comprising administering to the subject a pharmaceutical formulation comprising a solid ionic complex of an LHRH analogue and a carrier macromolecule, wherein the peptide content of said complex is 57% to 80% by weight.

6. The method of claim 5, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least one week after the pharmaceutical composition is administered to the subject.

7. The method of claim 5, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least two weeks after the pharmaceutical composition is administered to the subject.

8. The method of claim 5, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least three weeks after the pharmaceutical composition is administered to the subject.

after

9. The method of claim 5, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least four weeks after the pharmaceutical composition is administered to the subject.

10. The method of claim 5, wherein the LHRH analogue is an LHRH antagonist.

11. The method of claim 10, wherein the LHRH antagonist has the following structure: Ac-D-Nal.sup.1, 4-Cl-D-Phe.sup.2, D-Pal.sup.3, N-Me-Tyr.sup.5, D-Asn.sup.6, Lys(iPr).sup.8, D-Ala.sup.10 -LHRH.

12. The method of claim 5, wherein the carrier macromolecule is an anionic polymer.

13. The method of claim 5, wherein the carrier macromolecule is an anionic polyalcohol derivative, or fragment thereof, or a pharmaceutically acceptable salt thereof.

14. The method of claim 5, wherein the carrier macromolecule is an anionic polysaccharide derivative, or fragment thereof, or a pharmaceutically acceptable salt thereof.

15. The method of claim 5, wherein the carrier macromolecule is carboxymethylcellulose, or a pharmaceutically acceptable salt thereof.

selected

from the group consisting of algin, alginate, anionic acetate polymers, anionic acrylic polymers, xantham gums, anionic carageenan derivatives, anionic polygalacturonic acid derivatives, sodium starch glycolate, and fragments, derivatives and pharmaceutically acceptable salts thereof.

17. The method of claim 5, wherein the pharmaceutical formulation is administered to the subject by a parenteral route.

18. The method of claim 5, wherein the pharmaceutical formulation is administered to the subject orally.

19. The method of claim 5, wherein the pharmaceutical formulation is administered by intramuscular injection or subcutaneous/intradermal injection.

20. The method of claim 5, wherein the condition treatable with an LHRH analogue is a hormone dependent cancer.

21. The method of claim 20, wherein the hormone dependent cancer is prostate cancer.

22. The method of claim 5, wherein the condition treatable with an LHRH analogue is selected from the group consisting of benign prostatic hypertrophy, precocious puberty, endometriosis and uterine fibroids.

for 23. The method of claim 5, wherein the LHRH analogue is administered
in vitro **fertilization** or contraceptive purposes.

the 24. A pharmaceutical composition comprising a solid ionic complex of a pharmaceutically active peptide and a carrier macromolecule, wherein
peptide content of said complex is 57% to 80% by weight.

ionic 25. A pharmaceutical composition consisting essentially of a solid complex of a pharmaceutically active peptide and a carrier macromolecule, wherein the peptide content of said complex is 57% to
80% by weight.

wherein 26. The pharmaceutical composition of any one of claim 24 or 25,
the pharmaceutically active peptide is cationic and the carrier
macromolecule is anionic.

wherein 27. The pharmaceutical composition of any one of claim 24 or 25,
the pharmaceutically active peptidic compound is aniotic and the
carrier macromolecule is cationic.

wherein 28. The pharmaceutical composition of any one of claim 24 or 25,
the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least one week after the pharmaceutical composition is administered to the subject.

wherein 29. The pharmaceutical composition of any one of claim 24 or 25,
the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least two weeks after the pharmaceutical composition is administered to the subject.

wherein 30. The pharmaceutical composition of any one of claim 24 or 25,
the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least three weeks after the pharmaceutical composition is administered to the subject.

wherein 31. The pharmaceutical composition of any one of claim 24 or 25,
the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least four weeks after the pharmaceutical composition is administered to the subject.

wherein 32. The pharmaceutical composition of any one of claim 24 or 25,
the pharmaceutically active peptide is a multivalent cationic or
anionic

peptide.

33. The pharmaceutical composition of any one of claim 24 or 25, wherein the peptide is 5 to 20 amino acids in length.

34. The pharmaceutical composition of any one of claim 24 or 25, wherein the peptide is 1 to 15 amino acids in length.

35. The pharmaceutical composition of any one of claim 24 or 25, wherein the peptide is 8 to 12 amino acids in length.

36. The pharmaceutical composition of any one of claim 24 or 25, wherein the carrier macromolecule is an anionic polymer.

37. The pharmaceutical composition of any one of claim 24 or 25, wherein the carrier macromolecule is an anionic polyalcohol derivative, or fragment thereof.

38. The pharmaceutical composition of any one of claim 24 or 25, wherein the carrier macromolecule is an anionic polysaccharide derivative, or fragment thereof.

39. The pharmaceutical composition of any one of claim 24 or 25, wherein the carrier macromolecule is carboxymethylcellulose, or a fragment or derivative thereof.

40. The pharmaceutical composition of any one of claim 24 or 25, wherein the carrier macromolecule is selected from the group consisting of algin, alginate, anionic acetate polymers, anionic acrylic polymers, xantham gums, anionic carageenan derivatives, anionic polygalacturonic acid derivatives, sodium starch glycolate, and fragments, derivatives and pharmaceutically acceptable salts thereof.

41. The pharmaceutical composition of any one of claim 24 or 25, which is a lyophilized solid.

42. The pharmaceutical composition of any one of claim 24 or 25, wherein said solid ionic complex is suspended as a liquid suspension or dispersed as a semi-solid dispersion.

43. The pharmaceutical composition of any one of claim 24 or 25, wherein said pharmaceutically active peptide is an LHRH analogue.

44. The pharmaceutical composition of claim 43 wherein the LHRH analogue is an LHRH antagonist comprising a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a D-asparagine structure.

45. The pharmaceutical composition of claim 43 wherein the LHRH analogue is an LHRH antagonist comprising a peptide compound comprising a structure: A-B-C-D-E-F-G-H-I-J wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal B is His or 4-Cl-D-Phe C is Trp, D-Pal,

D-Nal, L-Nal, D-Pal(N-O), or D-Trp D is Ser E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile; F is D-Asn, D-Gln, or D-Thr; G is Leu or Trp; H is Lys(iPr), Gln, Met, or

Arg

I is Pro; and J is Gly-NH.sub.2 or D-Ala-NH.sub.2 ; or a pharmaceutically acceptable salt thereof.

46. The pharmaceutical composition of claim 43, wherein the LHRH analogue is an LHRH antagonist having the following structure: Ac-D-Nal.sup.1, 4-Cl-D-Phe.sup.2, D-Pal.sup.3, N-Me-Tyr.sup.5, D-Asn.sup.6, Lys(iPr).sup.8, D-Ala.sup.10 -LHRH.

47. The pharmaceutical composition of claim 43 wherein said pharmaceutically active peptide is an LHRH antagonist.

48. The pharmaceutical composition of claim 43, wherein the LHRH analogue is the LHRH agonist Leuprolide having the structure pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro(ethylamide)-Gly.

49. The pharmaceutical composition of claim 43, wherein the LHRH analogue is the LHRH antagonist **Cetrorelix** having the structure Ac-D-Nal-4-Cl-D-Phe-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala.

50. The pharmaceutical composition of any one of claim 24 or 25, wherein
said pharmaceutically active peptide is selected from the group consisting of bradykinin analogues, parathyroid hormone, adenocorticotrophic hormone, calcitonin, and vasopressin analogues.

L20 ANSWER 2 OF 7 USPATFULL

CLM What is claimed is:

1. A GnRH antagonist peptide having the formula: X-D-2Nal-(A)D-Phe-D-3Pal-Ser-Xaa.sub.5 -Xaa.sub.6 -Leu-Xaa.sub.8 -Pro-Xaa.sub.10 or a pharmaceutically acceptable salt thereof wherein: X is an acyl group having not more than 7 carbon atoms or Q, with Q being ##STR11## and with R being H or lower alkyl; A is 4Cl, 4F, 4Br, 4NO.sub.2, 4CH.sub.3, 4OCH.sub.3, 3,4C1.sub.2 or C.sup..alpha. Me4Cl; Xaa.sub.5 is 4Aph(Q.sub.1) or 4Amf(Q.sub.1) with Q.sub.1 being ##STR12## a D/L mixture of either, Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2), D-Lys(Nic), D-Cit, D-Hci or D-3Pal, with Q.sub.2 being For, Ac, 3-amino-1,2,4-triazole(atz), Q or Q.sub.1 ; Xaa.sub.8 is Lys(ipr), Arg, Har, Arg(Et.sub.2) or Har(Et.sub.2); and Xaa.sub.10 is D-Ala-ol or Ala-ol; provided however that the .alpha.-amino group of Xaa.sub.5 may optionally be methylated; and provided further that when Xaa.sub.6 contains D- or L-Hor or D- or L-Imz or a D/L mixture of either, Xaa.sub.5 may have Ac, For or 3-amino-1,2,4-triazole as Q.sub.1.

2. A GnRH antagonist peptide according to claim 1 wherein Q is carbamoyl or methylcarbamoyl.

3. A GnRH antagonist according to claim 1 wherein Q.sub.1 is L-Hor or D-Hor.

4. A GnRH antagonist according to claim 1 wherein X is Ac and Xaa.sub.8 is Lys(ipr).

5. A GnRH antagonist according to claim 1 wherein Xaa.sub.5 is 4Aph(L- or D-Hor) and Xaa.sub.6 is D-4Aph(Ac), D-4Aph(atz), or D-3Pal.

6. A GnRH antagonist according to claim 1 wherein Xaa.sub.5 is 4Aph(L- or D-Hor), Q.sub.2 is Q and R is H or methyl.

7. A GnRH antagonist according to claim 1 wherein Xaa.sup.5 is 4Aph(L-

or D-Hor) and Xaa.sub.6 is D-Cit or D-Hci.

8. A GnRH antagonist according to claim 1 wherein Xaa.sub.6 is D-4Aph(D-Hor).

9. A GnRH antagonist peptide according to claim 1 wherein: X is For, Ac,

Acr, Pn, By, Vl, Vac, Bz or Q; A is 4Cl or 4F; Xaa.sub.5 is 4Aph(Q.sub.1) or 4Amf(Q.sub.1) with Q.sub.1 being a D-isomer, an L-isomer, or a D/L-isomer mixture of either Hor or Imz; Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2), D-Cit, D-Lys(Nic) or D-3Pal, with Q.sub.2 being For, Ac, Q or Q.sub.1 ; and Xaa.sub.8 is Lys(ipr).

10. A GnRH antagonist according to claim 9 wherein Q.sub.1 is L- or D-Hor and Xaa.sub.6 is D-4Amf(Q), with R being H or methyl.

11. A GnRH antagonist according to claim 9 wherein X is Ac or Q; R is H or methyl; Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2) or D-3Pal, with Q.sub.2 being Ac, Q or Q.sub.1.

12. A GnRH antagonist according to claim 1 having the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-Xaa.sub.6 -Leu-Lys(ipr)-Pro-Xaa.sub.10, wherein Xaa.sub.6 is D-4Aph(Ac), D-3Pal, D-4Aph(carbamoyl), D-4Amf(carbamoyl), D-4Amf(methylcarbamoyl) or D-4Aph(D-Hor).

13. A pharmaceutical composition for inhibiting the secretion of gonadotropins in mammals comprising, as an active ingredient, an effective amount of a GnRH antagonist according to claim 12 in association with a nontoxic diluent.

FSH

14. A method for inhibiting the secretion of gonadotropins in mammals comprising administering an amount of a pharmaceutical composition according to claim 13 which effects a substantial decrease in LH and levels.

GnRH

15. A method for in vivo or in vitro diagnosis of a condition where is causing excess hormonal secretion or tumor growth, which method comprises administering a GnRH antagonist peptide according to claim 12 and monitoring for hormonal secretion or for tumor cell proliferation.

16. A GnRH antagonist according to claim 1 having either the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(carbamoyl)-Leu-Lys(ipr)-Pro-D-Ala-ol; or the formula Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(carbamoyl)-Leu-Lys(ipr)-Pro-Ala-ol.

X

17. A GnRH antagonist according to claim 1 having either the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Amf(carbamoyl)-Leu-Lys(ipr)-Pro-D-Ala-ol; or the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Amf(carbamoyl)-Leu-Lys(ipr)-Pro-Ala-ol.

18. A GnRH antagonist peptide having the formula: X-D-2Nal-(A)D-Phe-D-Pal-Ser-(N.sup..alpha. Me)Xaa.sub.5 -Xaa.sub.6 -Leu-Xaa.sub.8 -Pro-Xaa.sub.10 or a pharmaceutically acceptable salt thereof wherein:

##STR13##
is an acyl group having not more than 7 carbon atoms or Q, with Q being

##STR14##
or a D/L mixture of either, Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2), D-Lys(Nic), D-Cit, D-Hci or D-Pal, with Q.sub.2 being

For, Ac, 3-amino-1,2,4-triazole, Q or Q.sub.1 ; Xaa.sub.8 is Lys(ipr), Arg, Har, Arg(Et.sub.2) or Har(Et.sub.2); and Xaa.sub.10 is D-Ala-NH.sub.2, D-Ala-ol, Ala-ol, NHCH.sub.2 CH.sub.3, Gly-NH.sub.2, Ala-NH.sub.2, AzaGly-NH.sub.2, Agl-NH.sub.2, D-Agl-NH.sub.2, Agl(Me)-NH.sub.2 or D-Agl(Me)-NH.sub.2, provided however that when Xaa.sub.6 contains D- or L-Hor or D- or L-Imz or a D/L mixture of either, Xaa.sub.5 may have Ac, For or 3-amino-1,2,4-triazole as Q.sub.1.

19. A GnRH antagonist peptide according to claim 18 wherein Q is carbamoyl or methylcarbamoyl; Q.sub.1 is L-Hor or D-Hor; and Xaa.sub.10 is D-Ala-NH.sub.2, D-Ala-ol or Ala-ol.

20. A GnRH antagonist peptide according to claim 18 wherein: X is For, Ac, Acr, Pn, By, Vl, Vac, Bz or Q; A is 4Cl or 4F; Xaa.sub.5 is Aph(Q.sub.1) or Amf(Q.sub.1) with Q.sub.1 being a D-isomer, an L-isomer,
or a D/L-isomer mixture of either Hor or Imz; Xaa.sub.6 is
D-Aph(Q.sub.2), D-Amf(Q.sub.2), D-Cit, D-Lys(Nic) or D-Pal, with
Q.sub.2 being For, Ac, Q or Q.sub.1 ; and Xaa.sub.8 is Lys(ipr).

=> d 1 bib

L20 ANSWER 1 OF 7 USPATFULL DUPLICATE 1
AN 2001:14464 USPATFULL
TI Pharmaceutical formulations for sustained drug delivery
IN Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 6180608 B1 20010130
AI US 1997-988851 19971211 (8)
RLI Continuation-in-part of Ser. No. US 1996-762747, filed on 11 Dec 1996,
now patented, Pat. No. US 5968895
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner:
Delacroix-Muirheid, C.
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.